<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">EPMA J</journal-id><journal-id journal-id-type="iso-abbrev">EPMA J</journal-id><journal-title-group><journal-title>The EPMA Journal</journal-title></journal-title-group><issn pub-type="ppub">1878-5077</issn><issn pub-type="epub">1878-5085</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5121967</article-id><article-id pub-id-type="pmid">27904656</article-id><article-id pub-id-type="publisher-id">73</article-id><article-id pub-id-type="doi">10.1186/s13167-016-0073-3</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>The Berlin Treatment Algorithm: recommendations for tailored innovative therapeutic strategies for multiple sclerosis-related fatigue</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-8164-6393</contrib-id><name><surname>Veauthier</surname><given-names>Christian</given-names></name><address><email>Christian.veauthier@charite.de</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Hasselmann</surname><given-names>Helge</given-names></name><address><email>helge.hasselmann@charite.de</email></address><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Gold</surname><given-names>Stefan M.</given-names></name><address><email>stefan.gold@charite.de</email></address><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Paul</surname><given-names>Friedemann</given-names></name><address><email>Friedemann.paul@charite.de</email></address><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff5">5</xref><xref ref-type="aff" rid="Aff6">6</xref></contrib><aff id="Aff1"><label>1</label>Interdisciplinary Center for Sleep Medicine, Charit&#x000e9; &#x02013; Universit&#x000e4;tsmedizin Berlin, Charit&#x000e9;platz 1, 10117 Berlin, Germany </aff><aff id="Aff2"><label>2</label>NeuroCure Clinical Research Center, Charit&#x000e9; &#x02013; Universit&#x000e4;tsmedizin Berlin, Charit&#x000e9;platz 1, 10117 Berlin, Germany </aff><aff id="Aff3"><label>3</label>Department of Psychiatry and Psychotherapy, Charit&#x000e9; &#x02013; Universit&#x000e4;tsmedizin Berlin, Hindenburgdamm 30, 12203 Berlin, Germany </aff><aff id="Aff4"><label>4</label>Institute of Neuroimmunology and Multiple Sclerosis (INIMS), Center for Molecular Neurobiology (ZMNH), University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany </aff><aff id="Aff5"><label>5</label>Clinical and Experimental Multiple Sclerosis Research Center, Department of Neurology, Charit&#x000e9; &#x02013; Universit&#x000e4;tsmedizin Berlin, 10117 Berlin, Germany </aff><aff id="Aff6"><label>6</label>Experimental and Clinical Research Center, Max Delbr&#x000fc;ck Center for Molecular Medicine and Charit&#x000e9; &#x02013; Universit&#x000e4;tsmedizin Berlin, Berlin, Germany </aff></contrib-group><pub-date pub-type="epub"><day>24</day><month>11</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>24</day><month>11</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>7</volume><issue>1</issue><elocation-id>25</elocation-id><history><date date-type="received"><day>27</day><month>8</month><year>2016</year></date><date date-type="accepted"><day>21</day><month>10</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2016</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">More than 80% of multiple sclerosis (MS) patients suffer from fatigue. Despite this, there are few therapeutic options and evidence-based pharmacological treatments are lacking. The associated societal burden is substantial (MS fatigue is a major reason for part-time employment or early retirement), and at least one out of four MS patients view fatigue as the most burdensome symptom of their disease. The mechanisms underlying MS-related fatigue are poorly understood, and objective criteria for distinguishing and evaluating levels of fatigue and tiredness have not yet been developed. A further complication is that both symptoms may also be unspecific indicators of many other diseases (including depression, sleep disorders, anemia, renal failure, liver diseases, chronic obstructive pulmonary disease, drug side effects, recent MS relapses, infections, nocturia, cancer, thyroid hypofunction, lack of physical exercise). This paper reviews current treatment options of MS-related fatigue in order to establish an individualized therapeutic strategy that factors in existing comorbid disorders. To ensure that such a strategy can also be easily and widely implemented, a comprehensive approach is needed, which ideally takes into account all other possible causes and which is moreover cost efficient. Using a diagnostic interview, depressive disorders, sleep disorders and side effects of the medication should be identified and addressed. All MS patients suffering from fatigue should fill out the Modified Fatigue Impact Scale, Epworth Sleepiness Scale, the Beck Depression Inventory (or a similar depression scale), and the Pittsburgh Sleep Quality Index (or the Insomnia Severity Index). In some patients, polygraphic or polysomnographic investigations should be performed. The treatment of underlying sleep disorders, drug therapy with alfacalcidol or fampridine, exercise therapy, and cognitive behavioral therapy-based interventions may be effective against MS-related fatigue. The objectives of this article are to identify the reasons for fatigue in patients suffering from multiple sclerosis and to introduce individually tailored treatment approaches. Moreover, this paper focuses on current knowledge about MS-related fatigue in relation to brain atrophy and lesions, cognition, disease course, and other findings in an attempt to identify future research directions.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Polysomnography</kwd><kwd>Restless legs syndrome</kwd><kwd>Personalized medicine</kwd><kwd>Resistance training</kwd><kwd>Cognitive behavioral therapy</kwd><kwd>Obstructive sleep apnea</kwd><kwd>Patient stratification</kwd><kwd>Depression</kwd><kwd>Tiredness</kwd><kwd>Fatigue</kwd><kwd>Multiple sclerosis</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par47">Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative autoimmune disease of the central nervous system with multifactorial etiopathogenesis, which predominantly affects young adults and women [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR3">3</xref>]. At least one out of four MS patients views fatigue as the most burdensome symptom of their illness, and the majority of MS patients (more than 80%) suffer from fatigue [<xref ref-type="bibr" rid="CR4">4</xref>]. Fatigue may occur at any stage of the disease and can even precede MS onset by several years [<xref ref-type="bibr" rid="CR5">5</xref>]. Fatigue is a major reason for early retirement, reduced employment, and poor quality of life in people with MS [<xref ref-type="bibr" rid="CR6">6</xref>&#x02013;<xref ref-type="bibr" rid="CR8">8</xref>].</p><p id="Par48">The 1998 clinical practice guidelines recommended by the Consortium of Multiple Sclerosis Centers (the so-called MS Council, a consensus group of 22 North American associations including the American Academy of Neurology, the Consortium of Multiple Sclerosis Centers, and the US National Multiple Sclerosis Society) have defined MS-related fatigue as &#x0201c;a subjective lack of physical and/or mental energy that is perceived by the individual or caregiver to interfere with usual and desired activities&#x0201d; [<xref ref-type="bibr" rid="CR9">9</xref>]. According to this definition, fatigue not only is a symptom but also has a major impact on daily activities.</p><p id="Par49">The precise mechanisms of MS-related fatigue are not known, and several non-MS-related possible reasons for fatigue and tiredness should be taken into account [<xref ref-type="bibr" rid="CR2">2</xref>]. This paper reviews current data about MS-related fatigue and neuroanatomical findings, cognitive impairment, depression, disease-modifying therapies, and disease course, on the one hand, and major confounders and other (symptomatic) reasons for fatigue and tiredness, on the other. Furthermore, the aim of this paper is to provide physicians with a clinically applicable treatment algorithm for MS-related fatigue. This review is an updated and extended version of a recently published article in German [<xref ref-type="bibr" rid="CR10">10</xref>].</p></sec><sec id="Sec2"><title>Assessment and diagnostics</title><sec id="Sec3"><title>Fatigue questionnaires</title><p id="Par50">Several scales are available for measuring fatigue. The first published fatigue scale was the unidimensional Fatigue Severity Scale (FSS) in 1989 identifying the existence and severity of fatigue [<xref ref-type="bibr" rid="CR11">11</xref>]. Nine years later, the MS Council recommended the multidimensional Modified Fatigue Impact Scale (MFIS, 21 items), measuring the impact of fatigue on cognitive functioning and psychosocial as well as physical domains [<xref ref-type="bibr" rid="CR9">9</xref>]. The MFIS is an abbreviated version of the <italic>Fatigue Impact Scale</italic> (FIS, 40 items) [<xref ref-type="bibr" rid="CR12">12</xref>]. The FIS itself is a more concise version of the 138 items listed by the &#x0201c;Multiple Sclerosis Quality-of-Life Inventory&#x0201d; (MSQLI) [<xref ref-type="bibr" rid="CR13">13</xref>]. The FSS and the MFIS are not specific for MS-related fatigue and show an overlap with depression and tiredness due to sleep disorders [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. Most studies used a MFIS cutoff of 38 or 45 [<xref ref-type="bibr" rid="CR15">15</xref>&#x02013;<xref ref-type="bibr" rid="CR17">17</xref>]. For details about the psychometric data and validation of these questionnaires, please see a recent review [<xref ref-type="bibr" rid="CR2">2</xref>]. Finally, in 2009, the Fatigue Scale for Motor and Cognitive Functions (FSMC) was introduced [<xref ref-type="bibr" rid="CR18">18</xref>].</p></sec><sec id="Sec4"><title>MS fatigue and tiredness</title><p id="Par51">Unlike sleepiness, mental (cognitive) fatigue and tiredness cannot be measured by polysomnography or electroencephalography. Both can only be assessed indirectly by neuropsychological investigations or vigorimeter testing and handgrip performance [<xref ref-type="bibr" rid="CR19">19</xref>].</p><p id="Par52">Moreover, outside the specific context of MS, patients suffering from sleep disorders who were consecutively admitted to a sleep laboratory also showed high mean MFIS values (untreated sleep apnea 32.5, periodic limb movement disorder and restless legs syndrome 44.1, insomnia 33.5) [<xref ref-type="bibr" rid="CR14">14</xref>]. The same was found for the FSS. Compared with men and older patients, the MFIS and FSS values were higher in women and in young patients. This is of particular importance because young women are typically overrepresented among MS patients.</p><p id="Par53">In summary, no objective diagnostic criteria for distinguishing between MS- and non-MS-related tiredness and fatigue exist. For this reason, other possible underlying causes of these symptoms have to be taken into account.</p></sec><sec id="Sec5"><title>MS-related fatigue versus sleepiness</title><p id="Par54">MS-related fatigue and tiredness can clinically and objectively (by polysomnography and by the multiple sleep latency test) be distinguished from sleepiness: Sleepiness is defined by the propensity to fall asleep, often associated with an effort to avoid sleeping and is generally caused by sleep disorders or by disturbances of the circadian rhythm [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. Therefore, screening for sleepiness is very important in fatigued MS patients because sleepiness is an important indicator for an underlying sleep disorder [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. All fatigued patients should be asked about sleepiness and fill in the Epworth Sleepiness Scale (ESS). ESS values equal or greater than 10 indicate excessive daytime sleepiness (EDS), and in this case, patients should undergo polygraphy or polysomnography [<xref ref-type="bibr" rid="CR20">20</xref>].</p><p id="Par55">However, in sleep disorders outside the context of MS (in patients suffering from sleep disorders in the general population who are admitted to a sleep laboratory), fatigue and sleepiness can occur independently or simultaneously [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. The majority of them, almost two thirds, report pathological fatigue <italic>without</italic> sleepiness and almost one fifth fatigue <italic>and</italic> sleepiness. However, only a small number of patients with sleep disorders (4%) suffer from sleepiness and do not feel fatigued (13% experienced neither fatigue nor sleepiness) [<xref ref-type="bibr" rid="CR25">25</xref>]. This means that it is very important to ask MS patients about sleepiness, because sleepiness indicates sleep problems and is an argument against MS-related fatigue. However, these data show clearly that the lack of sleepiness is not an argument against the presence of sleep disorders: although sleepiness is more specific to an underlying sleep disorder, fatigue remains the most common symptom of an underlying sleep disorder.</p></sec><sec id="Sec6"><title>Fatigability and motor fatigue</title><p id="Par56">We have to distinguish between sustained perceived fatigue from load-dependent fatigability, on the one hand, and impaired performance during a motor task and an increased subjective experience of fatigue, on the other [<xref ref-type="bibr" rid="CR26">26</xref>]. Studies investigating load-dependent abnormal fatigability, maximal strength, subjective fatigue, and surface electromyography have shown a correlation between the changes in subjective fatigue and changes in strength in people with MS&#x02014;but not a relationship between subjective fatigue and the changes in the amplitude of the electromyography. In other words, repetitive motor tasks did not lead to a performance decline, but fatigue feelings clearly increased during a repetitive motor task [<xref ref-type="bibr" rid="CR27">27</xref>]. The increased experience of fatigue can be confounded by depression, and the objective signs of fatigability are normally not assessed in clinical praxis [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. Moreover, most published studies investigating MS-related fatigue assessed fatigue by questionnaires, as opposed to objective investigations.</p><p id="Par57">As mentioned above, the MFIS can be divided into three subscales. The nine items of the &#x0201c;physical subscale&#x0201d; measure motor fatigue. Patients can perceive physical (motor) fatigue and mental (cognitive) fatigue simultaneously. An exact definition of motor fatigue is lacking, but usually, motor fatigue is defined as a reduction in maximal walking distance that cannot be explained by the degree of paresis, ataxia, or spasticity [<xref ref-type="bibr" rid="CR30">30</xref>].</p><p id="Par58">Gait recording using a camera system and infrared markers attached to the patient&#x02019;s body and connected by cable to a unit worn on a belt allows the objective assessment of gait abnormalities after physical exertion and exhaustion. Therefore, the changes in gait parameters after physical exertion can be regarded as one possibility to distinguish objectively motor fatigue from fatigue by depression or normal tiredness&#x02014;a clear diagnostic statement which, unfortunately, is lacking in the domain of cognitive fatigue and tiredness [<xref ref-type="bibr" rid="CR30">30</xref>].</p><p id="Par59">Studies using functional magnetic resonance imaging (fMRI) to test whether a different pattern of movement-associated cortical and subcortical activation might contribute to the development of fatigue in patients with MS showed more significant activation of the contralateral primary somatomotor cortex, the ipsilateral rolandic operculum, and the thalamus, indicating impaired interaction between functionally related cortical and subcortical areas in motor fatigue [<xref ref-type="bibr" rid="CR31">31</xref>].</p></sec><sec id="Sec7"><title>Primary versus secondary fatigue</title><p id="Par60">Studies investigating MS-related fatigue distinguish between primary and secondary fatigue. Stankoff et al. state that &#x0201c;in some cases, fatigue may be secondary to depression, cognitive dysfunction, poor sleep, or motor impairment. Nevertheless, for many patients, fatigue exists independently of motor weakness, cognitive, or mood disorders: this primary fatigue&#x02026;.&#x0201d; [<xref ref-type="bibr" rid="CR16">16</xref>]. Yet the differentiation between primary fatigue (due to MS) and secondary fatigue (due to other diseases, e.g., depression and sleep disorders) is not always clear. The prevalence of restless legs syndrome (RLS) is four times higher in MS patients than in the general population and may be related to spinal cord damage [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]. So, are fatigued MS patients with RLS due to spinal cord lesions suffering from <italic>primary</italic> or <italic>secondary</italic> fatigue? What exactly is <italic>primary</italic> fatigue?</p></sec><sec id="Sec8"><title>Discrimination between fatigue, motor fatigue, tiredness, and sleepiness</title><p id="Par61">Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref> displays schematically the relationship between primary and secondary fatigue, tiredness, motor fatigue, and sleepiness. Whereas motor fatigue (as one aspect and a specific manifestation of primary fatigue) can be measured objectively by gait recording, mental (cognitive) primary fatigue cannot be distinguished objectively from tiredness and secondary fatigue. Sleepiness is completely different from primary or secondary fatigue or tiredness and can be measured objectively by multiple sleep latency test (MSLT) [<xref ref-type="bibr" rid="CR20">20</xref>].<fig id="Fig1"><label>Fig. 1</label><caption><p>Distinction between primary fatigue, secondary fatigue, and sleepiness. This figure displays possibilities for distinguishing the primary fatigue from secondary fatigue, tiredness, and sleepiness. Whereas primary motor fatigue can be distinguished objectively from tiredness and secondary fatigue by gait recording, primary&#x000a0;cognitive fatigue indeed cannot be distinguished objectively from tiredness and secondary fatigue. Sleepiness can clearly be distinguished from primary and secondary fatigue and motor fatigue and tiredness&#x02014;as sleepiness can be measured objectively by the multiple sleep latency test</p></caption><graphic xlink:href="13167_2016_73_Fig1_HTML" id="MO1"/></fig>
</p></sec></sec><sec id="Sec9"><title>Clinical correlates and biological mechanisms</title><sec id="Sec10"><title>Disease course and disability</title><p id="Par62">Patients with higher disability (according to the Expanded Disability Status Scale (EDSS)) [<xref ref-type="bibr" rid="CR34">34</xref>] suffer from fatigue more frequently [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR36">36</xref>], and older MS patients as well as those with longer disease duration tend to have more fatigue [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>]. Findings vary regarding disease course: Whereas some studies found fatigue to be more prevalent in progressive MS [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>], other studies were not able to confirm this relationship [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR38">38</xref>]. A recent study identified fatigue as an independent predictor of a subsequent MS diagnosis in a cohort of over 100 patients with a clinically isolated syndrome [<xref ref-type="bibr" rid="CR39">39</xref>].</p></sec><sec id="Sec11"><title>Cognitive function, neuropsychological deficits, depression, and fatigue</title><p id="Par63">MS is a complex neurological illness that is often accompanied by neuropsychiatric symptoms. Indeed, major depression is the most common comorbidity in MS [<xref ref-type="bibr" rid="CR40">40</xref>]. In addition, more than 60% of MS patients experience cognitive impairment during the course of their illness, with information processing, executive functioning, attention, and memory most commonly affected [<xref ref-type="bibr" rid="CR41">41</xref>&#x02013;<xref ref-type="bibr" rid="CR47">47</xref>]. Rather than broad cognitive impairment, MS is better characterized by relatively specific, domain-dependent deficits [<xref ref-type="bibr" rid="CR48">48</xref>]. However, accurate neuropsychological assessment is complicated in MS, because fatigue and depression themselves may have detrimental effects on cognitive function. For instance, poor performance could be confounded by comorbid depressive symptomatology or fatigue, especially as cognitive complaints can be subtle. For example, the Paced Auditory Serial Addition Test (PASAT), often used as a primary tool to assess working memory and processing speed [<xref ref-type="bibr" rid="CR49">49</xref>], may be vulnerable in repeated neuropsychological assessments to practice effects that obscure the impact of fatigue. More specifically, one study found that while PASAT performance increased with each trial, so did fatigue [<xref ref-type="bibr" rid="CR50">50</xref>].</p><p id="Par64">Similarly, while subjective fatigue has been associated with reduced cognitive performance [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR52">52</xref>], this relationship was not confirmed in other studies [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR53">53</xref>&#x02013;<xref ref-type="bibr" rid="CR56">56</xref>], indicating that the interplay between cognitive dysfunction and fatigue is more complex than could be expected from direct adverse effects of fatigue on quality of life or disability. Indeed, it has been suggested that while cognitive exhaustion may heighten levels of fatigue, severe fatigue does not necessarily reduce cognitive performance [<xref ref-type="bibr" rid="CR52">52</xref>].</p><p id="Par65">In line with the well-known effects of depression in healthy subjects, and despite earlier negative findings (e.g., [<xref ref-type="bibr" rid="CR57">57</xref>]), a review has corroborated the association between depression and cognitive function in MS [<xref ref-type="bibr" rid="CR58">58</xref>]. More specifically, it was shown that high levels of depression mainly affect cognitive functions that are resource intensive, such as attention, working memory, or planning [<xref ref-type="bibr" rid="CR59">59</xref>&#x02013;<xref ref-type="bibr" rid="CR61">61</xref>]. Notably, the adverse effects of depression may be mediated by reductions in processing speed [<xref ref-type="bibr" rid="CR62">62</xref>], which have also been observed in non-depressed patients with MS [<xref ref-type="bibr" rid="CR63">63</xref>&#x02013;<xref ref-type="bibr" rid="CR65">65</xref>].</p><p id="Par66">An international consortium of MS experts has recommended a battery of tests known as the &#x0201c;Minimal Assessment of Cognitive Function in Multiple Sclerosis&#x0201d; (MACFIMS) for routine monitoring of MS-associated cognitive impairment [<xref ref-type="bibr" rid="CR66">66</xref>]. The MACFIMS takes roughly 90&#x000a0;min to administer and assesses language (Controlled Oral Word Association Test), spatial processing (Judgment of Line Orientation Test), learning and memory (California Verbal Learning Test (CVLT)), Brief Visuospatial Memory Test (BVMT), processing speed, and working memory (Symbol Digit Modalities Test, PASAT) as well as executive function (Delis-Kaplan Executive Function System Sorting Test) [<xref ref-type="bibr" rid="CR66">66</xref>]. Alternatively, an abbreviated combination is available that takes approximately 15&#x000a0;min to complete (Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)) and includes the SDMT, CVLT-II (first five recall trials only), and BVMT-R (first three recall trials only) [<xref ref-type="bibr" rid="CR67">67</xref>].</p><p id="Par67">In summary, assessment of neuropsychological impairment in MS patients needs to factor in comorbid depression and fatigue. Particularly, cognitive tests that rely predominantly on processing speed may be vulnerable to bias.</p></sec><sec id="Sec12"><title>Fatigue and sleep disorders</title><p id="Par68">The Epworth Sleepiness Scale (ESS) is a screening tool that assesses sleepiness [<xref ref-type="bibr" rid="CR22">22</xref>], but normal values do not entirely rule out sleep disorders as these are not always associated with sleepiness. Two polysomnographic studies investigating sleep disorders and fatigue in consecutive MS patients have demonstrated a significant relationship between fatigue and sleep disorders [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR68">68</xref>]. Interestingly, a significant association existed between the presence of a sleep disorder and MFIS and FSS values, but not between fatigue and ESS values [<xref ref-type="bibr" rid="CR17">17</xref>]. Both former groups monitored their individual study subjects in an open follow-up study and found that sleep medical treatment significantly reduced fatigue; however, prospective controlled studies are lacking [<xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR70">70</xref>]. In the study by Veauthier et al., 49 out of 66 consecutive MS patients suffered from sleep disorders as confirmed by polysomnography [<xref ref-type="bibr" rid="CR17">17</xref>]. The most common sleep disorders diagnosed in MS are obstructive sleep apnea (OSA), insomnia, periodic limb movement disorder (PLMD), restless legs syndrome (RLS), and sleep disruption due to nocturia.</p><p id="Par69">Well-established diagnostic criteria that can accurately compare the prevalence of insomnia in the general population compared to MS patients are lacking. A discussion of insomnia in MS is provided in a recent review [<xref ref-type="bibr" rid="CR2">2</xref>]. Importantly, in the clinical setting, over-the-counter drugs against insomnia (for example, products that contain diphenhydramine) can lead to next-day fatigue [<xref ref-type="bibr" rid="CR71">71</xref>&#x02013;<xref ref-type="bibr" rid="CR73">73</xref>].</p><p id="Par70">As mentioned above, prevalence of RLS is four times higher in MS compared to the general population. MS patients with RLS also show higher EDSS values and significantly reduced cervical cord fractional anisotropy in MRI examinations compared with MS patients without RLS&#x02014;indicating a more pronounced cervical cord damage in MS patients with RLS [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR74">74</xref>, <xref ref-type="bibr" rid="CR75">75</xref>]. MS patients with more than ten periodic leg movements (PLMs) per hour of REM sleep showed a significantly higher disability measured by the EDSS [<xref ref-type="bibr" rid="CR33">33</xref>].</p><p id="Par71">With regards to MS and sleep apnea, it is currently unknown whether MS lesions can cause sleep apnea and whether the prevalence of sleep apnea is increased in MS [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR76">76</xref>]. In the general population, sleep apnea can cause depression, and conversely, the treatment of sleep apnea by continuous positive airway therapy (CPAP) can be effective in the treatment of depression [<xref ref-type="bibr" rid="CR77">77</xref>, <xref ref-type="bibr" rid="CR78">78</xref>]. This is especially important given the link between fatigue and depression in MS [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR79">79</xref>]. Studies investigating the impact of treatment for nocturia in MS fatigue are lacking, but only half of MS patients with moderate to severe overactive bladder symptoms are treated with an anticholinergic medication [<xref ref-type="bibr" rid="CR80">80</xref>].</p><p id="Par72">As polysomnographic assessment is time consuming, defining which patients should undergo the test is critical. In order to develop a screening instrument, we performed a retrospective receiver operating characteristic (ROC) analysis of the investigated MS patients investigated by polysomnography (PSG)&#x02014;using the MFIS for daytime dysfunction and the Pittsburgh Sleep Quality Index (PSQI) for sleep disturbances [<xref ref-type="bibr" rid="CR81">81</xref>, <xref ref-type="bibr" rid="CR82">82</xref>]. By jointly applying the MFIS cutoff of 34 and the PSQI cutoff of 5 (either MFIS&#x02009;&#x0003e;&#x02009;34 or PSQI&#x02009;&#x0003e;&#x02009;5), we achieved a sensitivity of 89.8% for sleep disorders (specificity 58.8%, positive predictive value 86.3%, negative predictive value 66.7%).</p></sec><sec id="Sec13"><title>Structural and functional MRI correlates</title><p id="Par73">As structural and diffuse brain damage are detectable from the earliest disease stages, multiple studies have attempted to relate fatigue severity assessed by different questionnaires and sometimes in conjunction with cognitive dysfunction to various neuroimaging findings acquired using structural, functional, and metabolic imaging modalities [<xref ref-type="bibr" rid="CR83">83</xref>&#x02013;<xref ref-type="bibr" rid="CR88">88</xref>]. For example, a magnetic resonance spectroscopy study has indicated decreased N-acetylaspartate-creatine ratios (NAA/Cr) as a marker of axonal metabolic integrity with increasing fatigue scores, suggesting diffuse and widespread axonal dysfunction as a contributor to fatigue in MS [<xref ref-type="bibr" rid="CR89">89</xref>]. Structural imaging studies focusing on the quantification of atrophy have reported an association of fatigue severity with atrophy in the thalamus and a number of different cortical gray matter regions (superior frontal and inferior parietal gyrus, parietal lobe) in patients with relapsing-remitting MS [<xref ref-type="bibr" rid="CR90">90</xref>, <xref ref-type="bibr" rid="CR91">91</xref>]. Yaldizli et al. found an association between callosal atrophy and fatigue and cognitive performance in a large cohort of MS patients with various disease courses [<xref ref-type="bibr" rid="CR92">92</xref>], and Nygaard et al. reported a relation between regionally smaller cortical surface areas and volumes and higher depression and fatigue scores in relapsing-remitting MS patients [<xref ref-type="bibr" rid="CR93">93</xref>]. Although Gobbi et al. did not find an association between white matter atrophy and lesion distribution [<xref ref-type="bibr" rid="CR94">94</xref>], a previous study by Sepulcre et al. suggested a correlation between T2 lesion load and fatigue severity and between fatigue scores and gray matter atrophy in frontal regions [<xref ref-type="bibr" rid="CR95">95</xref>]. Damasceno et al. found an association between fatigue severity and atrophy in various cortical and gray matter regions; however, after controlling for disability and depression, only caudate and accumbens volumes remained statistically significant (interestingly, the nucleus accumbens is an important mesolimbic structure involved in motivational and reward processes) [<xref ref-type="bibr" rid="CR96">96</xref>]. Caudate and basal ganglia were also identified as regions related to clinical fatigue by other imaging modalities. A positron emission tomography study by Roelcke et al. found reduced glucose metabolism in the frontal cortex and basal ganglia in MS patients with fatigue [<xref ref-type="bibr" rid="CR97">97</xref>], and in a resting-state fMRI study, Finke et al. showed that fatigue severity was negatively correlated with functional connectivity of the basal ganglia with the medial prefrontal cortex, precuneus, and posterior cingulate cortex [<xref ref-type="bibr" rid="CR98">98</xref>]. These connectivity changes suggest&#x02014;in line with the above mentioned study by Damasceno et al.&#x000a0;[<xref ref-type="bibr" rid="CR96">96</xref>]&#x02014;that impairment of both motor and non-motor functions of the basal ganglia, which also include reward processing and motivation, is involved in the pathophysiology of fatigue in MS. Another fMRI study applying a motor task by Rocca et al. found decreased activation of various frontal and temporal cortical regions and&#x02014;importantly&#x02014;the basal ganglia in MS patients with fatigue, versus MS patients without fatigue and healthy controls. The authors interpreted this as a maladaptation of motor network recruitment and a central contributor to fatigue [<xref ref-type="bibr" rid="CR99">99</xref>].</p><p id="Par74">Although these and other imaging studies provide interesting data on imaging correlates of fatigue and underscore that dopaminergic structures like the basal ganglia may be significantly related to the perception of fatigue, they merely describe statistical correlations or associations and do not shed light on causality. Moreover, comparability between studies is limited by the heterogeneity of the applied imaging modalities, the clinical cohorts assessed, and the fatigue questionnaires used, which likely at least in part accounts for the discrepancies between study findings. Moreover, in future studies, sleep disorders as a major cause for secondary fatigue and as an important confounder should be ruled out by polysomnography prior to study enrollment.</p></sec><sec id="Sec14"><title>Inflammation and neuroendocrine abnormalities</title><p id="Par75">One intriguing observation from animal models and experimental studies in humans is that cytokines and other inflammatory stimuli can induce sickness behavior symptoms, including anorexia, hypoactivity, and hyperthermia, that resemble some aspects of fatigue [<xref ref-type="bibr" rid="CR100">100</xref>&#x02013;<xref ref-type="bibr" rid="CR102">102</xref>]. This so-called sickness behavior has therefore been proposed as a pathobiological model of fatigue in the context of inflammatory disorders such as MS [<xref ref-type="bibr" rid="CR103">103</xref>]. However, clinical studies applying this model in the specific context of MS have yielded mixed results. Circulating levels of several inflammatory markers such as interleukin-2 (IL-2), neopterin, ICAM-1 (intercellular adhesion molecule 1), and C-reactive protein (CRP) were not correlated with fatigue [<xref ref-type="bibr" rid="CR104">104</xref>, <xref ref-type="bibr" rid="CR105">105</xref>]. In contrast, two studies examining proinflammatory cytokines such as TNF&#x003b1; (tumor necrosis factor alpha) (but not interferon-&#x003b3; (IFN&#x003b3;)) mRNA in lymphocytes [<xref ref-type="bibr" rid="CR106">106</xref>] and TNF&#x003b1; and IFN&#x003b3; protein production after in vitro stimulation [<xref ref-type="bibr" rid="CR107">107</xref>] reported positive correlations with fatigue. A study subsequent to the latter also found increased intracellular in vitro production of IFN&#x003b3; that correlated fatigue [<xref ref-type="bibr" rid="CR108">108</xref>]. These cytokines did not yield significant associations with fatigue scores in a more comprehensive serum cytokine screen, which however suggested an association of fatigue with interleukin-6 (IL-6) [<xref ref-type="bibr" rid="CR109">109</xref>].</p><p id="Par76">Beyond inflammatory markers, several studies have also investigated the relationship between alterations in neuroendocrine systems, such as the hypothalamo-pituitary-adrenal (HPA) axis, and MS-related fatigue. Again, study findings were mixed. Whereas Gottschalk et al. found a higher activity of the HPA axis in MS fatigue patients, as evidenced by significantly increased adrenocorticotropin (ACTH) concentrations, Heesen et al. reported that HPA-axis feedback-regulation (as determined by the Dex-CRH suppression test) axis activity was not related to fatigue [<xref ref-type="bibr" rid="CR107">107</xref>, <xref ref-type="bibr" rid="CR110">110</xref>]. Resting levels of cortisol (as measured by a single midday blood sample) were also not associated with fatigue in another study [<xref ref-type="bibr" rid="CR111">111</xref>]. More recently, one study reported an association of fatigue in relapsing-remitting MS (RR-MS) with lower waking cortisol levels and an increased response to awakening (cortisol awakening response (CAR)), indicating that cortisol could play a role in the perception of fatigue [<xref ref-type="bibr" rid="CR112">112</xref>], but two studies assessing the circadian slope of cortisol secretion did not find an association with MS fatigue [<xref ref-type="bibr" rid="CR108">108</xref>, <xref ref-type="bibr" rid="CR112">112</xref>].</p><p id="Par77">In summary, while the role of inflammation in the pathobiology of &#x0201c;fatigue-like&#x0201d; symptoms is well supported by animal models and experimental studies in humans, no individual immune or neuroendocrine markers have consistently been associated with fatigue in MS. Some of this might be due to the large heterogeneity of markers, challenge paradigms, and the definition of fatigue used in each particular study. Moreover, in light of the abovementioned high prevalence of sleep disorders in MS fatigue, future studies investigating the neuroinflammatory and neuroendocrine aspects of MS-associated fatigue should take care to apply polysomnography to exclude possible bias resulting from sleep disorders as confounder.</p></sec><sec id="Sec15"><title>Methodical limitations and further research direction</title><p id="Par78">Diversity between study cohorts (e.g., with or without secondary progression, level of disability, treatment na&#x000ef;ve or not) is a long-standing problem hampering definitive interpretation of research into MS as a whole. The investigation of MS-related fatigue is additionally complicated by a lack of standardization between fatigue scales and, even more seriously, by the fact that the potential confounders (sleep disorders and drug side effects) are not excluded as a matter of course. Definitively identifying mutual relationships between distinct parameters (imaging or depression or disease course or cognitive dysfunction or sleep disorders or inflammation and fatigue) across different studies becomes neigh on impossible. To date, not one study into MS-related fatigue has examined all parameters and excluded all known confounders. Such a task would be even more difficult in the context of urgently needed large multicenter studies.</p></sec></sec><sec id="Sec16"><title>Treatment of MS fatigue</title><sec id="Sec17"><title>Immune therapy and fatigue</title><p id="Par79">The same methodical limitations apply to the published data on the impact of MS treatment on fatigue. The lack of studies investigating the influence of existing MS therapies on MS fatigue as a primary endpoint and the influence of other confounders, such as age, disease course and duration, questionnaires used, medication, comorbid disorders (e.g., depression), and the lack of a control group in most studies, have hampered insight into the effect of disease-modifying therapies on MS-related fatigue. However, a number of studies suggest that beta interferons and glatiramer acetate (GA) reduce fatigue (with GA treatment potentially more effective) [<xref ref-type="bibr" rid="CR113">113</xref>&#x02013;<xref ref-type="bibr" rid="CR116">116</xref>]. The effect of natalizumab on fatigue varied between studies [<xref ref-type="bibr" rid="CR117">117</xref>, <xref ref-type="bibr" rid="CR118">118</xref>]. Whereas Penner et al. found that fatigue levels remained constant or decreased in the majority of patients after 1&#x000a0;year of natalizumab treatment, Kunkel et al. found no significant changes, although this may have been due to the study&#x02019;s small cohort size [<xref ref-type="bibr" rid="CR117">117</xref>, <xref ref-type="bibr" rid="CR118">118</xref>].</p><p id="Par80">Some limited results show that fingolimod might improve fatigue after changing from beta interferon to fingolimod (but not from GA) [<xref ref-type="bibr" rid="CR119">119</xref>, <xref ref-type="bibr" rid="CR120">120</xref>]. However, no evidence exists that teriflunomide, dimethyl fumarate, or alemtuzumab improve fatigue [<xref ref-type="bibr" rid="CR121">121</xref>&#x02013;<xref ref-type="bibr" rid="CR123">123</xref>]. In fact, one study identified fatigue as a side effect of dimethyl fumarate treatment [<xref ref-type="bibr" rid="CR122">122</xref>].</p></sec><sec id="Sec18"><title>Management strategies recommended by the MS Council</title><p id="Par81">As fatigue is not specific or unique to MS [<xref ref-type="bibr" rid="CR124">124</xref>&#x02013;<xref ref-type="bibr" rid="CR126">126</xref>], in 1998, the MS Council for Clinical Practice Guidelines recommended performing blood tests and evaluating comorbid medical conditions, iatrogenic factors, depression or psychological distress, sleep disturbances, and, where applicable, as next diagnostic step sleep studies (polysomnography and multiple sclerosis latency test) [<xref ref-type="bibr" rid="CR9">9</xref>]. Chronic obstructive pulmonary disease (COPD) should also be excluded [<xref ref-type="bibr" rid="CR9">9</xref>]. After ruling out or addressing any comorbid medical conditions, drug therapy, (aerobic) exercise, and, among others, self-management strategies were recommended. Self-management strategies included activities such as cessation of smoking, modifying dietary habits, optimizing time management, adjusting activity levels, taking naps, consumption of cool beverages, cool showers and baths for heat intolerance, exercise programs, or engaging in relaxation exercises.</p></sec><sec id="Sec19"><title>Drug therapy</title><p id="Par82">One recently published trial (alfacalcidol versus placebo) showed a significant reduction of fatigue under therapy with alfacalcidol (an active vitamin D3 metabolite requiring activation in the liver) [<xref ref-type="bibr" rid="CR127">127</xref>]. Further studies are needed in order to confirm this effect. Apart from vitamin D, in recent studies, modafinil, amantadine, carnitine, or pemoline [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR128">128</xref>&#x02013;<xref ref-type="bibr" rid="CR136">136</xref>] have generally not been found to be effective in treating MS-related fatigue. Our review of the literature found six meta-analyses of the randomized controlled trials (modafinil, amantadine, carnitine, and pemoline) [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR128">128</xref>, <xref ref-type="bibr" rid="CR130">130</xref>, <xref ref-type="bibr" rid="CR131">131</xref>, <xref ref-type="bibr" rid="CR133">133</xref>&#x02013;<xref ref-type="bibr" rid="CR135">135</xref>, <xref ref-type="bibr" rid="CR137">137</xref>&#x02013;<xref ref-type="bibr" rid="CR140">140</xref>]. Whereas one meta-analysis investigating three studies published before 1996 found a significant effect of amantadine superior to placebo [<xref ref-type="bibr" rid="CR141">141</xref>], five other meta-analyses analyzing these three studies and further recent studies did not report any significant effect of the investigated drugs [<xref ref-type="bibr" rid="CR129">129</xref>, <xref ref-type="bibr" rid="CR136">136</xref>, <xref ref-type="bibr" rid="CR142">142</xref>&#x02013;<xref ref-type="bibr" rid="CR144">144</xref>]. One study, however, did find a significant improvement of fatigue under treatment with carnitine compared to amantadine [<xref ref-type="bibr" rid="CR140">140</xref>]. Aspirin was found to be an effective treatment for fatigue in another study [<xref ref-type="bibr" rid="CR145">145</xref>], although this was countered by a subsequent study comparing aspirin with amantadine treatment [<xref ref-type="bibr" rid="CR130">130</xref>].</p></sec><sec id="Sec20"><title>Motor fatigue and fampridine</title><p id="Par83">4-Aminopyridine (dalfampridine, fampridine), a potassium channel blocker, is approved by the US Food and Drug Administration, Health Canada, and the European Medicines Agency as a treatment for MS-related walking ability [<xref ref-type="bibr" rid="CR146">146</xref>]. Clinical trials have shown improvement in walking speed compared to placebo (the percentage of MS patients with an improvement in 6-min walk test of &#x0003e;20% (45.1%) was significantly greater with dalfampridine relative to placebo (14.3%)) [<xref ref-type="bibr" rid="CR146">146</xref>, <xref ref-type="bibr" rid="CR147">147</xref>].</p><p id="Par84">Furthermore, two studies showed that fampridine improves MS fatigue as assessed using the visual analog scale (VAS), the MFIS, and the FSS [<xref ref-type="bibr" rid="CR148">148</xref>, <xref ref-type="bibr" rid="CR149">149</xref>]. Treatment with fampridine should be stopped immediately in patients presenting with hypersensitivity symptoms, such as swollen face, mouth, lips, throat or tongue, reddening or itching of the skin, chest tightness and breathing problems, and seizures (up to 1 in 100 people). A number of other unpleasant but harmless side effects exist, including urinary tract infection (&#x0003e;10%) and dizziness, headache, sleep disturbances, and anxiety (&#x0003c;10%). Fampridine is contraindicated in patients with a creatinine clearance lower than 80&#x000a0;ml/min, and therefore, renal function should be monitored. Initial prescription should be limited to 2&#x000a0;weeks of therapy, which is the duration needed to assess clinical benefit. Extension of treatment should be subject to improvement as assessed by a timed walking test. If no improvement is observed at this point, the fampridine treatment should be discontinued. Fampridine is contraindicated during pregnancy.</p></sec><sec id="Sec21"><title>Fatigue management interventions, rehabilitation intervention and cognitive behavioral therapy</title><p id="Par85">Rehabilitation (exercise or physical therapy, educational interventions such as mindfulness training, self-management program, vestibular rehabilitation) and cognitive behavioral therapy (CBT) are significantly effective against MS-related fatigue [<xref ref-type="bibr" rid="CR136">136</xref>, <xref ref-type="bibr" rid="CR150">150</xref>&#x02013;<xref ref-type="bibr" rid="CR153">153</xref>]. Moreover, internet-based CBT has been investigated and could play a greater role in the future [<xref ref-type="bibr" rid="CR154">154</xref>, <xref ref-type="bibr" rid="CR155">155</xref>].</p><p id="Par86">A 2014 systematic review and meta-analysis by Asano and Finlayson compared pharmacotherapy, exercise, and educational interventions for MS-related fatigue [<xref ref-type="bibr" rid="CR136">136</xref>], suggesting that the eight reports of educational approaches yielded a significant overall effect with an effect size of 0.54 (95% CI 0.30&#x02013;0.77, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001). In particular, the three trials that used CBT exhibited the largest effect within the educational intervention subsection of the review [<xref ref-type="bibr" rid="CR154">154</xref>&#x02013;<xref ref-type="bibr" rid="CR156">156</xref>]. One additional trial has been published since the above review combining CBT with energy conservation. Here, too, significantly reduced fatigue was found (standardized effect size 0.54). A follow-up analysis found that some of the effects were maintained at 12&#x000a0;months post-trial [<xref ref-type="bibr" rid="CR157">157</xref>].</p><p id="Par87">Overall, strong evidence exists that educational interventions have a definitive moderate ability to reduce MS-related fatigue. It should be noted that the studies surveyed were generally combined elements of CBT, mindfulness, skill training, and educational components. Published evidence to date suggests that CBT-based interventions are the most effective elements of a fatigue management program (see Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). Finally, the settings of these interventions also vary from group to one-on-one sessions or from in-person to telephone or internet intervention. The available trials (see Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>) suggest that individual intervention might yield larger effects than group interventions; however, this has not been formally studied to date. For the time being, the setting used should be based on the resources available and the specific needs and requirements of the patient population. Remote access options like telephone or Internet sessions might be particularly suitable for patients with mobility problems or patients in rural areas.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Trials using educational interventions in MS-related fatigue</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Sample size</th><th>Intervention</th><th>Effect size (according to meta-analysis by Asano and Finlayson)</th></tr></thead><tbody><tr><td>Mohr et al. 2003 [<xref ref-type="bibr" rid="CR156">156</xref>]</td><td>60</td><td>CBT (individual sessions)</td><td>0.80 (0.19&#x02013;1.42)</td></tr><tr><td>Mathiowetz et al. 2005 [<xref ref-type="bibr" rid="CR188">188</xref>]</td><td>169</td><td>Fatigue management program (energy conservation course) (group sessions)</td><td>0.42 (0.08&#x02013;0.76)</td></tr><tr><td>Kos et al. 2007 [<xref ref-type="bibr" rid="CR189">189</xref>]</td><td>51</td><td>Multidisciplinary fatigue management program (group sessions)</td><td>&#x02212;0.16 (&#x02212;0.72 to 0.38)</td></tr><tr><td>Van Kessel et al. 2008 [<xref ref-type="bibr" rid="CR155">155</xref>]</td><td>72</td><td>CBT (individual and phone sessions)</td><td>0.99 (0.50&#x02013;1.48)</td></tr><tr><td>Grossman et al. 2010 [<xref ref-type="bibr" rid="CR150">150</xref>]</td><td>150</td><td>Mindfulness (group sessions)</td><td>0.42 (0.09&#x02013;0.74)</td></tr><tr><td>Hugos et al. 2010 [<xref ref-type="bibr" rid="CR190">190</xref>]</td><td>30</td><td>Fatigue management program (group sessions)</td><td>0.43 (&#x02212;0.29 to 1.57)</td></tr><tr><td>Finlayson et al. 2011 [<xref ref-type="bibr" rid="CR191">191</xref>]</td><td>190</td><td>Fatigue management program (phone sessions)</td><td>0.53 (0.19&#x02013;0.86)</td></tr><tr><td>Moss-Morris et al. 2012 [<xref ref-type="bibr" rid="CR154">154</xref>]</td><td>40</td><td>CBT (online + phone sessions)</td><td>1.11 (0.43&#x02013;1.78)</td></tr><tr><td>Thomas et al. 2013 [<xref ref-type="bibr" rid="CR157">157</xref>]</td><td>164</td><td>CBT + energy effectiveness training (group)</td><td>0.54 (not included in meta-analysis)</td></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec22"><title>Treatment of underlying sleep disorders</title><p id="Par88">The first step to addressing MS-related fatigue is diagnosing and treating any underlying sleep disorders. Two studies of sleep disorders and fatigue in consecutive MS patients have demonstrated a significant relationship between fatigue and sleep disorders [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR68">68</xref>]. In the study by Veauthier et al., 96% of fatigued MS patients were suffering from a sleep disorder [<xref ref-type="bibr" rid="CR17">17</xref>]. Sleep disorders are frequent in MS and have been significantly associated with higher MFIS values. MS patients suffering from sleep disorders show increased MFIS values compared to MS patients who are not suffering from sleep disorders (SD &#x000b1;42.8 versus &#x000b1;20.5, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001) [<xref ref-type="bibr" rid="CR17">17</xref>]. Besides depression and disability, sleep disturbances decrease health-related quality of life (HRQoL) [<xref ref-type="bibr" rid="CR158">158</xref>, <xref ref-type="bibr" rid="CR159">159</xref>]. Although OSA is a prevalent pathological condition and represents an increased risk for cardiovascular diseases, a majority of patients remain undiagnosed [<xref ref-type="bibr" rid="CR160">160</xref>, <xref ref-type="bibr" rid="CR161">161</xref>]. In particular, MS patients suffering from comorbid obstructive sleep apnea (OSA) or insomnia showed significantly decreased HRQoL for the &#x0201c;sleep&#x0201d; area (sleep subscale). But furthermore, OSA and insomnia patients show increased values in the &#x0201c;energy&#x0201d; and &#x0201c;emotional&#x0201d; subscales as well indicating that sleep disorders lead to impaired daytime functioning (and in OSA patients also for &#x0201c;physical abilities&#x0201d;) [<xref ref-type="bibr" rid="CR158">158</xref>].</p><p id="Par89">The most important sleep disorders in this context are OSA, insomnia, periodic limb movement disorder (PLMD), restless legs syndrome (RLS), and nocturia [<xref ref-type="bibr" rid="CR2">2</xref>]. In two open follow-up studies, the treatment of an underlying sleep disorder (continuous positive airway pressure (CPAP) for OSA, drug therapy and CBT for insomnia, and drug therapy for RLS and PLMD) significantly reduced fatigue, but prospective controlled studies are lacking [<xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR70">70</xref>].</p><p id="Par90">Many studies investigating fatigue have used the Epworth Sleepiness Scale (ESS) as a screening tool for sleep disorders [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR162">162</xref>]. That is not entirely correct. The ESS is a diagnostic instrument for sleepiness, not fatigue, and is especially recommended in the context of hypersomnia, OSA, and narcolepsy. A part of patients suffering from sleep disorders feel sleepy, but a significant proportion does not feel sleepy but rather fatigued. Therefore, the ESS is not a suitable questionnaire for all sleep disorders. In insomnia and other sleep disorders like RLS or PLMD, specific questionnaires are recommended: the Pittsburgh Sleep Quality Index (PSQI) or the Insomnia Severity Index (ISI) for insomnia and the RLS Diagnostic Index (RLS-DI) for RLS [<xref ref-type="bibr" rid="CR81">81</xref>, <xref ref-type="bibr" rid="CR163">163</xref>, <xref ref-type="bibr" rid="CR164">164</xref>]. These questionnaires cannot reflect the complex symptoms of sleep disorders and are only screening tools&#x02014;clinical interview by a sleep expert and objective testing (polysomnography) are the gold standard of sleep medical diagnosis.</p></sec><sec id="Sec23"><title>The Berlin Treatment Algorithm</title><p id="Par91">It is one thing to recommend the treatment of underlying sleep disorders in this issue in general, but another to say which patient has to be sent to the sleep specialist or sleep laboratory. Because of the complexity of the issue and due to the fact that clinicians need some practical instructions, the discussion of the different treatment options does not replace the need for a practical guide with specific procedures and measures. We would like to take the opportunity to introduce our Berlin Treatment Algorithm of MS fatigue, which we developed in the last years. Figure&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref> outlines the treatment algorithm.<fig id="Fig2"><label>Fig. 2</label><caption><p>The Berlin Treatment Algorithm. Please note: Restless legs syndrome can be diagnosed on the basis of the following four minimal criteria: an urge to move the legs (usually accompanied by uncomfortable sensations), which begin or worsen during rest and are relieved by movement predominantly in the evening or night. Depression can be diagnosed by structured interviews. Self-report scales (e.g., Beck Depression Inventory (BDI)) can be useful to screen for depression. Abbreviations: <italic>MFIS</italic> Modified Fatigue Impact Scale, <italic>PSQI</italic> Pittsburgh Sleep Quality Index, <italic>ESS</italic> Epworth Sleepiness Scale, <italic>COPD</italic> chronic obstructive pulmonary disease, <italic>SSRIs</italic> selective serotonin reuptake inhibitors, <italic>CBT</italic> cognitive behavioral therapy</p></caption><graphic xlink:href="13167_2016_73_Fig2_HTML" id="MO2"/></fig>
</p><sec id="Sec24"><title>Phase A: basic recommendations</title><p id="Par92">The Berlin Treatment Algorithm follows the recommendations of the MS Council for Clinical Practice Guidelines as a first step: As an initial step, blood tests should be performed to rule out anemia, thyroid dysfunction, renal and hepatic insufficiency, vitamin D deficiency, and infections. In cases of possible COPD (due to smoking), pulmonary function tests and blood gas analysis are also recommended. At this stage, medical history questionnaires should also address a patient&#x02019;s use of sedative drugs, including over-the-counter medicines, which might worsen fatigue. Weaning or reducing patient consumption of such drugs would be the next necessary step. If the patient has recently been suffering from fatigue, a neurological examination should be performed to rule out relapse or disease progression and&#x000a0;an MRI should be performed in order to assess radiographic disease activity [<xref ref-type="bibr" rid="CR165">165</xref>]. Once the above confounders have either been addressed or excluded, the patient should fill out the MFIS and the PSQI. Then, all patients with higher MFIS values &#x0003e;34 and/or PSQI values &#x0003e;5 should enter the next phase.</p></sec><sec id="Sec25"><title>Phase B: specific therapy</title><p id="Par93">At this stage, possible causes of fatigue should be identified by a diagnostic interview. The latter should include questions about both current and past fatigue symptoms and focus mainly on determining whether nocturia, depression, and sleep disorders (OSA, insomnia, RLS, behaviorally induced insufficient sleep syndrome (BIISS)) play a role [<xref ref-type="bibr" rid="CR21">21</xref>].</p><sec id="FPar1"><title>Restless legs syndrome</title><p id="Par94">RLS is defined by an urge to move the legs, usually accompanied by uncomfortable and unpleasant sensations in the legs, which is partially or totally relieved by movement. The discomfort begins or worsens during periods of rest or inactivity and in the evening or at night on condition that its occurrence is not solely accounted for as symptoms primary to another medical or a behavioral condition [<xref ref-type="bibr" rid="CR166">166</xref>]. RLS is often misdiagnosed in MS patients, and RLS-associated symptoms are often misinterpreted as spasticity in more disabled patients.</p><p>Treatment of RLS symptoms consists of iron supplementation, if ferritin serum levels are lower than 75&#x000a0;mcg/l, and dopaminergic drugs [<xref ref-type="bibr" rid="CR167">167</xref>&#x02013;<xref ref-type="bibr" rid="CR169">169</xref>]. Pregabalin is effective against RLS symptoms as well, but it is not approved in some countries for the treatment of RLS [<xref ref-type="bibr" rid="CR170">170</xref>].</p><p>The questionnaire <italic>Restless Legs Syndrome Diagnostic Index</italic> (RLS-DI) is used as a screening tool; however, this cannot replace a diagnostic interview by a sleep expert. The International RLS Study Group (IRLSSG) rating scale should be used for the assessment of the response to therapy [<xref ref-type="bibr" rid="CR164">164</xref>, <xref ref-type="bibr" rid="CR171">171</xref>].</p></sec><sec id="FPar2"><title>Insomnia</title><p id="Par97">Whereas impaired sleep maintenance can be an unspecific symptom of sleep disorders in general (OSA, insomnia, and others), delayed sleep onset with prolonged sleep latencies before falling asleep is a clear indication for sleep-onset insomnia. Such patients can be treated with sleep restriction therapy and sleep hygiene education, relaxing routine within an hour before bedtime, regular exercise, avoiding daytime napping, and late heavy meals [<xref ref-type="bibr" rid="CR172">172</xref>, <xref ref-type="bibr" rid="CR173">173</xref>]. Sleep restriction is an easy and very efficacious therapy against sleep-onset insomnia [<xref ref-type="bibr" rid="CR174">174</xref>]. Prescription and over-the-counter drug therapies include short-acting non-benzodiazepine sedative-hypnotic agents; ramelteon, a melatonin receptor agonist; trazodone; antidepressants; and sedating antihistamines [<xref ref-type="bibr" rid="CR175">175</xref>]. Thyroid hyperfunction should be ruled out, and coffee should be avoided (in particular, in the afternoon and evening).</p></sec><sec id="FPar3"><title>Behaviorally induced insufficient sleep syndrome</title><p id="Par98">Sleepiness may be caused by behaviorally induced insufficient sleep syndrome (BIISS), which can only be diagnosed by a detailed medical history [<xref ref-type="bibr" rid="CR21">21</xref>]. Doctors should not only ask about sleep problems, but also about time spent in bed (currently and in the past, on workdays, and at weekends) and about fatigue severity during workdays and during holidays. Longer sleep times on the weekend or during holidays point to BIISS. Sleep diaries or actigraphy may be helpful. In severe cases, referral to a sleep expert can be necessary [<xref ref-type="bibr" rid="CR167">167</xref>].</p></sec><sec id="FPar4"><title>Obstructive sleep apnea</title><p id="Par99">If patients suffer from sleepiness (especially in case of ESS values &#x02265;10), they should be referred to a sleep specialist or admitted to a sleep laboratory, for assessment of possible narcolepsy, hypersomnia, or (more frequently) obstructive sleep apnea; symptoms of the latter include snoring, non-restorative sleep, morning headaches, dry mouth, nocturnal gasping or apnea, cardiovascular diseases, increased neck circumference, obesity, and a family history of OSA [<xref ref-type="bibr" rid="CR20">20</xref>].</p></sec><sec id="FPar5"><title>Nocturia</title><p id="Par100">Patients with nocturia (&#x02265;2 times per night) should be referred to a urologist, and a treatment with an anticholinergic or alpha-blocker should be considered [<xref ref-type="bibr" rid="CR80">80</xref>, <xref ref-type="bibr" rid="CR176">176</xref>].</p></sec><sec id="FPar6"><title>Depression</title><p id="Par101">Depression should be diagnosed using current criteria (e.g., Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) [<xref ref-type="bibr" rid="CR177">177</xref>] or the International Statistical Classification of Diseases and Related Health Problems (ICD-10) [<xref ref-type="bibr" rid="CR178">178</xref>]). This should ideally be done using standardized tools such as structured diagnostic interviews by experienced clinicians. Self-report scales such as the Beck Depression Inventory (BDI-II) can be used as a screening tool to identify patients requiring further diagnostic work-up. Recommended cutoffs for the general population are BDI values &#x0003e;13 in treated depressed patients and BDI-II &#x0003e;21 in treatment na&#x000ef;ve patients [<xref ref-type="bibr" rid="CR179">179</xref>]. For MS patients, these cutoffs might need to be adjusted to optimize sensitivity and specificity, depending on the clinical context [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR180">180</xref>]. As a brief screening tool, the two-item approach by Mohr and colleagues has been recommended by the American Academy of Neurology (AAN) task force [<xref ref-type="bibr" rid="CR156">156</xref>, <xref ref-type="bibr" rid="CR181">181</xref>].</p><p>In cases of depression, the treatment should include tailored treatment algorithms and multimodal approaches and a comprehensive treatment should include primarily psychotherapy and optionally pharmacotherapy [<xref ref-type="bibr" rid="CR182">182</xref>]. Selective serotonin reuptake inhibitors (SSRIs) are generally considered to be an effective and well-tolerated first-line treatment [<xref ref-type="bibr" rid="CR183">183</xref>]. The guidelines published by the AAN did not recommend antidepressant pharmacotherapy for depression in MS due to a lack of conclusive evidence; however, more recently, a meta-analysis reported overall beneficial effects [<xref ref-type="bibr" rid="CR181">181</xref>, <xref ref-type="bibr" rid="CR184">184</xref>, <xref ref-type="bibr" rid="CR185">185</xref>]. Cognitive behavioral therapy and mindfulness-based interventions have shown efficacy in improving depressive disorders in MS [<xref ref-type="bibr" rid="CR181">181</xref>, <xref ref-type="bibr" rid="CR185">185</xref>].</p></sec></sec><sec id="Sec26"><title>Phase C: drug therapy</title><p id="Par103">Fampridine prescribed for walking ability may be effective against fatigue as well, and one recent published randomized controlled trial (RCT) showed a substantial improvement of fatigue under therapy with vitamin D (alfacalcidol, if blood calcium levels are not higher than 10.5&#x000a0;mg/dl)&#x02014;but despite the substantial psychosocial burden of MS-related fatigue, there are no pharmacological treatments formally approved by regulatory authorities [<xref ref-type="bibr" rid="CR127">127</xref>, <xref ref-type="bibr" rid="CR129">129</xref>, <xref ref-type="bibr" rid="CR136">136</xref>, <xref ref-type="bibr" rid="CR149">149</xref>, <xref ref-type="bibr" rid="CR186">186</xref>]. Despite poor evidence, individual attempts to improve fatigue with modafinil, amantadine or carnitine may be undertaken.&#x000a0;</p></sec><sec id="Sec27"><title>Phase D: intensified sleep medical therapy</title><p id="Par104">Patients without improvement in fatigue following measures undertaken during the preceding phases should be admitted to a sleep laboratory in order to diagnose or exclude other underlying sleep disorders according to the ICSD-3 (International Classification of Sleep Disorders, Third Edition), which cannot be diagnosed by the diagnostic interview and questionnaires alone (for example, sleep-related breathing disorders including central apnea, obstructive sleep apnea, obesity hypoventilation syndrome, periodic limb movement disorder, parasomnia, insomnia) [<xref ref-type="bibr" rid="CR20">20</xref>]. In some cases, a specified sleep medical treatment (continuous positive airway pressure (CPAP) or drug therapy) can be started and fatigue may improve.</p></sec><sec id="Sec28"><title>Phase E: rehabilitation and cognitive behavioral therapy</title><p id="Par105">If fatigue persists, patients should participate in exercise therapy (aerobic exercise or resistance training) at least once a week or CBT [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR183">183</xref>]. This can be undertaken individually or as part of a group therapy and would be facilitated by tertiary MS centers collaborating with physical therapists or physical medicine and rehabilitation specialists in order to develop interned-based and cost-effective interventions.</p></sec></sec></sec><sec id="Sec29"><title>Outlook</title><p id="Par106">In the future, novel approaches such as smartphone&#x02013;based applications might play a role in measuring performance and patient-reported outcomes and improving fatigue by self-management strategies [<xref ref-type="bibr" rid="CR187">187</xref>].</p></sec><sec id="Sec30"><title>Conclusions</title><p id="Par107">The treatment of MS-related fatigue remains a challenging task, particularly due to the lack of a proven pharmacological therapy. However, many other therapeutic strategies have been shown to be effective in the treatment of MS-related fatigue. Therefore, a comprehensive approach including self-management strategies, rehabilitation, CBT, and the treatment of underlying sleep disorders and potentially other comorbidities is reasonable. The aim of the algorithm presented is to provide the treating physicians with a practical guide facilitating diagnosis and treatment of MS fatigue in individual patients.</p><sec id="Sec31"><title>Expert recommendation</title><p id="Par108">Personalized medicine is a promising new therapeutic strategy in order to treat MS-related fatigue. The treatment of fatigue should be tailored to the MS patients&#x02014;taking into account comorbid disorders such as RLS, insomnia, depression, history of snoring and sleep apnea, nocturia, and sleep deprivation as well as side effects of the medication. Patients with high MFIS or PSQI values indicating a high risk of sleep disorders should be investigated by polygraphy or polysomnography.</p></sec></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>AAN</term><def><p id="Par2">American Academy of Neurology</p></def></def-item><def-item><term>ACTH</term><def><p id="Par3">Adrenocorticotropic hormone</p></def></def-item><def-item><term>BDI-II</term><def><p id="Par4">Beck Depression Inventory</p></def></def-item><def-item><term>BICAMS</term><def><p id="Par5">Brief International Cognitive Assessment for Multiple Sclerosis</p></def></def-item><def-item><term>BIISS</term><def><p id="Par6">Behaviorally induced insufficient sleep syndrome</p></def></def-item><def-item><term>BVMT</term><def><p id="Par7">Brief Visuospatial Memory Test</p></def></def-item><def-item><term>CAR</term><def><p id="Par8">Cortisol awakening response</p></def></def-item><def-item><term>CBT</term><def><p id="Par9">Cognitive behavioral therapy</p></def></def-item><def-item><term>COPD</term><def><p id="Par10">Chronic obstructive pulmonary disease</p></def></def-item><def-item><term>CPAP</term><def><p id="Par11">Continuous positive airway pressure</p></def></def-item><def-item><term>CRP</term><def><p id="Par12">C-reactive protein</p></def></def-item><def-item><term>CVLT</term><def><p id="Par13">California Verbal Learning Test</p></def></def-item><def-item><term>DSM-V</term><def><p id="Par14">Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition</p></def></def-item><def-item><term>EDSS</term><def><p id="Par15">Expanded Disability Status Scale</p></def></def-item><def-item><term>ESS</term><def><p id="Par16">Epworth Sleepiness Scale</p></def></def-item><def-item><term>FIS</term><def><p id="Par17">Fatigue Impact Scale</p></def></def-item><def-item><term>fMRI</term><def><p id="Par18">Functional magnetic resonance imaging</p></def></def-item><def-item><term>FSMC</term><def><p id="Par19">Fatigue Scale for Motor and Cognitive Functions</p></def></def-item><def-item><term>FSS</term><def><p id="Par20">Fatigue Severity Scale</p></def></def-item><def-item><term>GA</term><def><p id="Par21">Glatiramer acetate</p></def></def-item><def-item><term>HPA</term><def><p id="Par22">Hypothalamo-pituitary-adrenal</p></def></def-item><def-item><term>HRQoL</term><def><p id="Par23">Health-related quality of life</p></def></def-item><def-item><term>ICAM-1</term><def><p id="Par24">Intercellular adhesion molecule 1</p></def></def-item><def-item><term>ICD-10</term><def><p id="Par25">International Statistical Classification of Diseases and Related Health Problems</p></def></def-item><def-item><term>ICSD-3</term><def><p id="Par26">International Classification of Sleep Disorders, Third Edition</p></def></def-item><def-item><term>IFN&#x003b3;</term><def><p id="Par27">Interferon-&#x003b3;</p></def></def-item><def-item><term>IL-2/IL-6</term><def><p id="Par28">Interleukin-2/-6</p></def></def-item><def-item><term>MACFIMS</term><def><p id="Par29">Minimal Assessment of Cognitive Function in Multiple Sclerosis</p></def></def-item><def-item><term>MFIS</term><def><p id="Par30">Modified Fatigue Impact Scale</p></def></def-item><def-item><term>MS</term><def><p id="Par31">Multiple sclerosis</p></def></def-item><def-item><term>MSLT</term><def><p id="Par32">Multiple sleep latency test</p></def></def-item><def-item><term>MSQLI</term><def><p id="Par33">Multiple Sclerosis Quality-of-Life Inventory</p></def></def-item><def-item><term>NAA/Cr</term><def><p id="Par34">N-acetylaspartate-creatine ratio</p></def></def-item><def-item><term>OSA</term><def><p id="Par35">Obstructive sleep apnea</p></def></def-item><def-item><term>PASAT</term><def><p id="Par36">Paced Auditory Serial Addition Test</p></def></def-item><def-item><term>PLMD</term><def><p id="Par37">Periodic limb movement disorder</p></def></def-item><def-item><term>PSG</term><def><p id="Par38">Polysomnography</p></def></def-item><def-item><term>PSQI</term><def><p id="Par39">Pittsburgh Sleep Quality Index</p></def></def-item><def-item><term>RCT</term><def><p id="Par40">Randomized controlled trial</p></def></def-item><def-item><term>RLS</term><def><p id="Par41">Restless legs syndrome</p></def></def-item><def-item><term>RLS-DI</term><def><p id="Par42">RLS Diagnostic Index</p></def></def-item><def-item><term>ROC</term><def><p id="Par43">Receiver operating characteristic</p></def></def-item><def-item><term>RR-MS</term><def><p id="Par44">Relapsing-remitting MS</p></def></def-item><def-item><term>SSRIs</term><def><p id="Par45">Selective serotonin reuptake inhibitors</p></def></def-item><def-item><term>TNF&#x003b1;</term><def><p id="Par46">Tumor necrosis factor alpha</p></def></def-item></def-list></glossary><ack><title>Acknowledgements</title><p>Not applicable.</p><sec id="FPar7"><title>Funding</title><p id="Par109">None.</p></sec><sec id="FPar8"><title>Availability of data and materials</title><p id="Par110">The data and articles mentioned in this review are published on PubMed.</p></sec><sec id="FPar9"><title>Authors&#x02019; contributions</title><p id="Par111">CV developed the Berlin Treatment Algorithm, was responsible for the study design, and wrote the text, excluding the sections on neuroimaging, neuroinflammation, and neuropsychology. He reviewed the literature and the neuroimaging, neuroinflammation, and neuropsychology section and is responsible for final approval of the version to be published, together with FP. He is accountable for all aspects of the work and ensuring that questions of accuracy or integrity of any part of the work are appropriately investigated and resolved. HH wrote the chapter on neuropsychology and participated in editing the article. SG wrote the chapters on neuroinflammation/neuroendocrinology, depression, and behavioral interventions and participated in editing the article. FP contributed substantially to the concept and design, contributed to the drafting and revision of the manuscript, and wrote the neuroimaging chapter. Together with CV, he is responsible for final approval of the version to be published. He is accountable for all aspects of the work and ensuring that questions of accuracy or integrity of any part of the work were appropriately investigated and resolved. Authors read and approved the final manuscript.</p></sec><sec id="FPar10"><title>Competing interests</title><p id="Par112">The authors declare that they have no competing interests.</p></sec><sec id="FPar11"><title>Consent for publication</title><p id="Par113">Not applicable</p></sec><sec id="FPar12"><title>Ethics approval and consent to participate</title><p id="Par114">Not applicable</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borisow</surname><given-names>N</given-names></name><name><surname>D&#x000f6;ring</surname><given-names>A</given-names></name><name><surname>Pfueller</surname><given-names>CF</given-names></name><name><surname>Paul</surname><given-names>F</given-names></name><name><surname>D&#x000f6;rr</surname><given-names>J</given-names></name><name><surname>Hellwig</surname><given-names>K</given-names></name></person-group><article-title>Expert recommendations to personalization of medical approaches in treatment of multiple sclerosis: an overview of family planning and pregnancy</article-title><source>EPMA J</source><year>2012</year><volume>3</volume><issue>1</issue><fpage>9</fpage><pub-id pub-id-type="doi">10.1186/1878-5085-3-9</pub-id><?supplied-pmid 22738272?><pub-id pub-id-type="pmid">22738272</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veauthier</surname><given-names>C</given-names></name><name><surname>Paul</surname><given-names>F</given-names></name></person-group><article-title>Sleep disorders in multiple sclerosis and their relationship to fatigue</article-title><source>Sleep Med</source><year>2014</year><volume>15</volume><issue>1</issue><fpage>5</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/j.sleep.2013.08.791</pub-id><?supplied-pmid 24360534?><pub-id pub-id-type="pmid">24360534</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="other">Konieczka K, Koch S, Binggeli T, Schoetzau A, Kesselring J. Multiple sclerosis and primary vascular dysregulation (Flammer syndrome). EPMA J. 2016;7(1). Available from: <ext-link ext-link-type="uri" xlink:href="http://epmajournal.biomedcentral.com/articles/10.1186/s13167-016-0062-6">http://epmajournal.biomedcentral.com/articles/10.1186/s13167-016-0062-6</ext-link>.</mixed-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krupp</surname><given-names>LB</given-names></name><name><surname>Alvarez</surname><given-names>LA</given-names></name><name><surname>LaRocca</surname><given-names>NG</given-names></name><name><surname>Scheinberg</surname><given-names>LC</given-names></name></person-group><article-title>Fatigue in multiple sclerosis</article-title><source>Arch Neurol</source><year>1988</year><volume>45</volume><issue>4</issue><fpage>435</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1001/archneur.1988.00520280085020</pub-id><?supplied-pmid 3355400?><pub-id pub-id-type="pmid">3355400</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berger</surname><given-names>JR</given-names></name><name><surname>Pocoski</surname><given-names>J</given-names></name><name><surname>Preblick</surname><given-names>R</given-names></name><name><surname>Boklage</surname><given-names>S</given-names></name></person-group><article-title>Fatigue heralding multiple sclerosis</article-title><source>Mult Scler</source><year>2013</year><volume>19</volume><issue>11</issue><fpage>1526</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1177/1352458513477924</pub-id><?supplied-pmid 23439577?><pub-id pub-id-type="pmid">23439577</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chua</surname><given-names>AS</given-names></name><name><surname>Glanz</surname><given-names>BI</given-names></name><name><surname>Guarino</surname><given-names>AJ</given-names></name><name><surname>Cook</surname><given-names>SL</given-names></name><name><surname>Greeke</surname><given-names>EE</given-names></name><name><surname>Little</surname><given-names>GE</given-names></name><etal/></person-group><article-title>Patient-reported outcomes in multiple sclerosis: relationships among existing scales and the development of a brief measure</article-title><source>Mult Scler Relat Disord</source><year>2015</year><volume>4</volume><issue>6</issue><fpage>598</fpage><lpage>606</lpage><pub-id pub-id-type="doi">10.1016/j.msard.2015.09.004</pub-id><?supplied-pmid 26590669?><pub-id pub-id-type="pmid">26590669</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>P</given-names></name><name><surname>Harding</surname><given-names>KE</given-names></name><name><surname>Clarkson</surname><given-names>H</given-names></name><name><surname>Pickersgill</surname><given-names>TP</given-names></name><name><surname>Wardle</surname><given-names>M</given-names></name><name><surname>Robertson</surname><given-names>NP</given-names></name></person-group><article-title>Demographic and clinical factors associated with changes in employment in multiple sclerosis</article-title><source>Mult Scler</source><year>2013</year><volume>19</volume><issue>12</issue><fpage>1647</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1177/1352458513481396</pub-id><?supplied-pmid 23652213?><pub-id pub-id-type="pmid">23652213</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coyne</surname><given-names>KS</given-names></name><name><surname>Boscoe</surname><given-names>AN</given-names></name><name><surname>Currie</surname><given-names>BM</given-names></name><name><surname>Landrian</surname><given-names>AS</given-names></name><name><surname>Wandstrat</surname><given-names>TL</given-names></name></person-group><article-title>Understanding drivers of employment changes in a multiple sclerosis population</article-title><source>Int J MS Care</source><year>2015</year><volume>17</volume><issue>5</issue><fpage>245</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.7224/1537-2073.2014-051</pub-id><?supplied-pmid 26472946?><pub-id pub-id-type="pmid">26472946</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="other">Paralyzed Veterans of America, editor. Fatigue and multiple sclerosis: evidence-based management strategies for fatigue in multiple sclerosis. Washington, DC; 1998. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.pva.org/site/apps/ka/ec/product.asp?c=ajIRK9NJLcJ2E&#x00026;b=6423003&#x00026;en=4dLxHFOfF3LGLPOiF2IDLLNsEhJIKLMkEbKJJWOAJrE&#x00026;ProductID=907097">http://www.pva.org/site/apps/ka/ec/product.asp?c=ajIRK9NJLcJ2E&#x00026;b=6423003&#x00026;en=4dLxHFOfF3LGLPOiF2IDLLNsEhJIKLMkEbKJJWOAJrE&#x00026;ProductID=907097</ext-link>.</mixed-citation></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="other">Veauthier C, Paul F. Therapie der Fatigue bei Multipler Sklerose, ein Behandlungsalgorithmus. Nervenarzt. 2016, doi:10.1007/s00115-016-0128-7.</mixed-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krupp</surname><given-names>LB</given-names></name><name><surname>LaRocca</surname><given-names>NG</given-names></name><name><surname>Muir-Nash</surname><given-names>J</given-names></name><name><surname>Steinberg</surname><given-names>AD</given-names></name></person-group><article-title>The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus</article-title><source>Arch Neurol</source><year>1989</year><volume>46</volume><issue>10</issue><fpage>1121</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1001/archneur.1989.00520460115022</pub-id><?supplied-pmid 2803071?><pub-id pub-id-type="pmid">2803071</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fisk</surname><given-names>JD</given-names></name><name><surname>Ritvo</surname><given-names>PG</given-names></name><name><surname>Ross</surname><given-names>L</given-names></name><name><surname>Haase</surname><given-names>DA</given-names></name><name><surname>Marrie</surname><given-names>TJ</given-names></name><name><surname>Schlech</surname><given-names>WF</given-names></name></person-group><article-title>Measuring the functional impact of fatigue: initial validation of the fatigue impact scale</article-title><source>Clin Infect Dis</source><year>1994</year><volume>18</volume><issue>Suppl 1</issue><fpage>S79</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1093/clinids/18.Supplement_1.S79</pub-id><?supplied-pmid 8148458?><pub-id pub-id-type="pmid">8148458</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fischer</surname><given-names>JS</given-names></name><name><surname>LaRocca</surname><given-names>NG</given-names></name><name><surname>Miller</surname><given-names>DM</given-names></name><name><surname>Ritvo</surname><given-names>PG</given-names></name><name><surname>Andrews</surname><given-names>H</given-names></name><name><surname>Paty</surname><given-names>D</given-names></name></person-group><article-title>Recent developments in the assessment of quality of life in multiple sclerosis (MS)</article-title><source>Mult Scler</source><year>1999</year><volume>5</volume><issue>4</issue><fpage>251</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1191/135245899678846177</pub-id><?supplied-pmid 10467384?><pub-id pub-id-type="pmid">10467384</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veauthier</surname><given-names>C</given-names></name></person-group><article-title>Younger age, female sex, and high number of awakenings and arousals predict fatigue in patients with sleep disorders: a retrospective polysomnographic observational study</article-title><source>Neuropsychiatr Dis Treat</source><year>2013</year><volume>9</volume><fpage>1483</fpage><pub-id pub-id-type="doi">10.2147/NDT.S50763</pub-id><?supplied-pmid 24109185?><pub-id pub-id-type="pmid">24109185</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flachenecker</surname><given-names>P</given-names></name><name><surname>K&#x000fc;mpfel</surname><given-names>T</given-names></name><name><surname>Kallmann</surname><given-names>B</given-names></name><name><surname>Gottschalk</surname><given-names>M</given-names></name><name><surname>Grauer</surname><given-names>O</given-names></name><name><surname>Rieckmann</surname><given-names>P</given-names></name><etal/></person-group><article-title>Fatigue in multiple sclerosis: a comparison of different rating scales and correlation to clinical parameters</article-title><source>Mult Scler</source><year>2002</year><volume>8</volume><issue>6</issue><fpage>523</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1191/1352458502ms839oa</pub-id><?supplied-pmid 12474995?><pub-id pub-id-type="pmid">12474995</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stankoff</surname><given-names>B</given-names></name><name><surname>Waubant</surname><given-names>E</given-names></name><name><surname>Confavreux</surname><given-names>C</given-names></name><name><surname>Edan</surname><given-names>G</given-names></name><name><surname>Debouverie</surname><given-names>M</given-names></name><name><surname>Rumbach</surname><given-names>L</given-names></name><etal/></person-group><article-title>Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study</article-title><source>Neurology</source><year>2005</year><volume>64</volume><issue>7</issue><fpage>1139</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1212/01.WNL.0000158272.27070.6A</pub-id><?supplied-pmid 15824337?><pub-id pub-id-type="pmid">15824337</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veauthier</surname><given-names>C</given-names></name><name><surname>Radbruch</surname><given-names>H</given-names></name><name><surname>Gaede</surname><given-names>G</given-names></name><name><surname>Pfueller</surname><given-names>C</given-names></name><name><surname>Dorr</surname><given-names>J</given-names></name><name><surname>Bellmann-Strobl</surname><given-names>J</given-names></name><etal/></person-group><article-title>Fatigue in multiple sclerosis is closely related to sleep disorders: a polysomnographic cross-sectional study</article-title><source>Mult Scler</source><year>2011</year><volume>17</volume><issue>5</issue><fpage>613</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1177/1352458510393772</pub-id><?supplied-pmid 21278050?><pub-id pub-id-type="pmid">21278050</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Penner</surname><given-names>I</given-names></name><name><surname>Raselli</surname><given-names>C</given-names></name><name><surname>Stocklin</surname><given-names>M</given-names></name><name><surname>Opwis</surname><given-names>K</given-names></name><name><surname>Kappos</surname><given-names>L</given-names></name><name><surname>Calabrese</surname><given-names>P</given-names></name></person-group><article-title>The Fatigue Scale for Motor and Cognitive Functions (FSMC): validation of a new instrument to assess multiple sclerosis-related fatigue</article-title><source>Mult Scler</source><year>2009</year><volume>15</volume><issue>12</issue><fpage>1509</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1177/1352458509348519</pub-id><?supplied-pmid 19995840?><pub-id pub-id-type="pmid">19995840</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greim</surname><given-names>B</given-names></name><name><surname>Benecke</surname><given-names>R</given-names></name><name><surname>Zettl</surname><given-names>UK</given-names></name></person-group><article-title>Qualitative and quantitative assessment of fatigue in multiple sclerosis (MS)</article-title><source>J Neurol</source><year>2007</year><volume>254</volume><issue>S2</issue><fpage>II58</fpage><lpage>64</lpage><?supplied-pmid 17503131?><pub-id pub-id-type="pmid">17503131</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="other">American Academy of Sleep Medicine, editor. International Classification of Sleep Disorders. 3rd ed. Darien, IL: American Academy of Sleep Medicine; 2014.</mixed-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marti</surname><given-names>I</given-names></name><name><surname>Valko</surname><given-names>PO</given-names></name><name><surname>Khatami</surname><given-names>R</given-names></name><name><surname>Bassetti</surname><given-names>CL</given-names></name><name><surname>Baumann</surname><given-names>CR</given-names></name></person-group><article-title>Multiple sleep latency measures in narcolepsy and behaviourally induced insufficient sleep syndrome</article-title><source>Sleep Med</source><year>2009</year><volume>10</volume><issue>10</issue><fpage>1146</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1016/j.sleep.2009.03.008</pub-id><?supplied-pmid 19464232?><pub-id pub-id-type="pmid">19464232</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johns</surname><given-names>MW</given-names></name></person-group><article-title>Reliability and factor analysis of the Epworth Sleepiness Scale</article-title><source>Sleep</source><year>1992</year><volume>15</volume><issue>4</issue><fpage>376</fpage><lpage>81</lpage><?supplied-pmid 1519015?><pub-id pub-id-type="pmid">1519015</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="other">Popp RFJ, Fierlbeck AK, Kn&#x000fc;ttel H, K&#x000f6;nig N, Rupprecht R, Weissert R, et al. Daytime sleepiness versus fatigue in patients with multiple sclerosis: a systematic review on the Epworth sleepiness scale as an assessment tool. Sleep Med Rev. 2016,&#x000a0;doi:10.1016/j.smrv.2016.03.004.</mixed-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aguillard</surname><given-names>RN</given-names></name><name><surname>Riedel</surname><given-names>BW</given-names></name><name><surname>Lichstein</surname><given-names>KL</given-names></name><name><surname>Grieve</surname><given-names>FG</given-names></name><name><surname>Johnson</surname><given-names>CT</given-names></name><name><surname>Noe</surname><given-names>SL</given-names></name></person-group><article-title>Daytime functioning in obstructive sleep apnea patients: exercise tolerance, subjective fatigue, and sleepiness</article-title><source>Appl Psychophysiol Biofeedback</source><year>1998</year><volume>23</volume><issue>4</issue><fpage>207</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1023/A:1022257514209</pub-id><?supplied-pmid 10457812?><pub-id pub-id-type="pmid">10457812</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hossain</surname><given-names>JL</given-names></name><name><surname>Ahmad</surname><given-names>P</given-names></name><name><surname>Reinish</surname><given-names>LW</given-names></name><name><surname>Kayumov</surname><given-names>L</given-names></name><name><surname>Hossain</surname><given-names>NK</given-names></name><name><surname>Shapiro</surname><given-names>CM</given-names></name></person-group><article-title>Subjective fatigue and subjective sleepiness: two independent consequences of sleep disorders?</article-title><source>J Sleep Res</source><year>2005</year><volume>14</volume><issue>3</issue><fpage>245</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2869.2005.00466.x</pub-id><?supplied-pmid 16120099?><pub-id pub-id-type="pmid">16120099</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kluger</surname><given-names>BM</given-names></name><name><surname>Krupp</surname><given-names>LB</given-names></name><name><surname>Enoka</surname><given-names>RM</given-names></name></person-group><article-title>Fatigue and fatigability in neurologic illnesses: proposal for a unified taxonomy</article-title><source>Neurology</source><year>2013</year><volume>80</volume><issue>4</issue><fpage>409</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e31827f07be</pub-id><?supplied-pmid 23339207?><pub-id pub-id-type="pmid">23339207</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Severijns</surname><given-names>D</given-names></name><name><surname>Octavia</surname><given-names>JR</given-names></name><name><surname>Kerkhofs</surname><given-names>L</given-names></name><name><surname>Coninx</surname><given-names>K</given-names></name><name><surname>Lamers</surname><given-names>I</given-names></name><name><surname>Feys</surname><given-names>P</given-names></name></person-group><article-title>Investigation of fatigability during repetitive robot-mediated arm training in people with multiple sclerosis</article-title><source>PLoS One</source><year>2015</year><volume>10</volume><issue>7</issue><fpage>e0133729</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0133729</pub-id><?supplied-pmid 26213990?><pub-id pub-id-type="pmid">26213990</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Behrens</surname><given-names>J</given-names></name><name><surname>Pf&#x000fc;ller</surname><given-names>C</given-names></name><name><surname>Mansow-Model</surname><given-names>S</given-names></name><name><surname>Otte</surname><given-names>K</given-names></name><name><surname>Paul</surname><given-names>F</given-names></name><name><surname>Brandt</surname><given-names>AU</given-names></name></person-group><article-title>Using perceptive computing in multiple sclerosis&#x02014;the Short Maximum Speed Walk test</article-title><source>J Neuroeng Rehabil</source><year>2014</year><volume>11</volume><fpage>89</fpage><pub-id pub-id-type="doi">10.1186/1743-0003-11-89</pub-id><?supplied-pmid 24886525?><pub-id pub-id-type="pmid">24886525</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Behrens</surname><given-names>JR</given-names></name><name><surname>Mertens</surname><given-names>S</given-names></name><name><surname>Kr&#x000fc;ger</surname><given-names>T</given-names></name><name><surname>Grobelny</surname><given-names>A</given-names></name><name><surname>Otte</surname><given-names>K</given-names></name><name><surname>Mansow-Model</surname><given-names>S</given-names></name><etal/></person-group><article-title>Validity of visual perceptive computing for static posturography in patients with multiple sclerosis</article-title><source>Mult Scler</source><year>2016</year><volume>22</volume><issue>12</issue><fpage>1596</fpage><lpage>1606</lpage><pub-id pub-id-type="doi">10.1177/1352458515625807</pub-id><?supplied-pmid 26814201?><pub-id pub-id-type="pmid">26814201</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sehle</surname><given-names>A</given-names></name><name><surname>M&#x000fc;ndermann</surname><given-names>A</given-names></name><name><surname>Starrost</surname><given-names>K</given-names></name><name><surname>Sailer</surname><given-names>S</given-names></name><name><surname>Becher</surname><given-names>I</given-names></name><name><surname>Dettmers</surname><given-names>C</given-names></name><etal/></person-group><article-title>Objective assessment of motor fatigue in multiple sclerosis using kinematic gait analysis: a pilot study</article-title><source>J Neuroeng Rehabil</source><year>2011</year><volume>8</volume><fpage>59</fpage><pub-id pub-id-type="doi">10.1186/1743-0003-8-59</pub-id><?supplied-pmid 22029427?><pub-id pub-id-type="pmid">22029427</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Filippi</surname><given-names>M</given-names></name><name><surname>Rocca</surname><given-names>MA</given-names></name><name><surname>Colombo</surname><given-names>B</given-names></name><name><surname>Falini</surname><given-names>A</given-names></name><name><surname>Codella</surname><given-names>M</given-names></name><name><surname>Scotti</surname><given-names>G</given-names></name><etal/></person-group><article-title>Functional magnetic resonance imaging correlates of fatigue in multiple sclerosis</article-title><source>NeuroImage</source><year>2002</year><volume>15</volume><issue>3</issue><fpage>559</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1006/nimg.2001.1011</pub-id><?supplied-pmid 11848698?><pub-id pub-id-type="pmid">11848698</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manconi</surname><given-names>M</given-names></name><name><surname>Rocca</surname><given-names>MA</given-names></name><name><surname>Ferini-Strambi</surname><given-names>L</given-names></name><name><surname>Tortorella</surname><given-names>P</given-names></name><name><surname>Agosta</surname><given-names>F</given-names></name><name><surname>Comi</surname><given-names>G</given-names></name><etal/></person-group><article-title>Restless legs syndrome is a common finding in multiple sclerosis and correlates with cervical cord damage</article-title><source>Mult Scler</source><year>2008</year><volume>14</volume><issue>1</issue><fpage>86</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1177/1352458507080734</pub-id><?supplied-pmid 17942519?><pub-id pub-id-type="pmid">17942519</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veauthier</surname><given-names>C</given-names></name><name><surname>Gaede</surname><given-names>G</given-names></name><name><surname>Radbruch</surname><given-names>H</given-names></name><name><surname>Sieb</surname><given-names>J-P</given-names></name><name><surname>Wernecke</surname><given-names>K-D</given-names></name><name><surname>Paul</surname><given-names>F</given-names></name></person-group><article-title>Periodic limb movements during REM sleep in multiple sclerosis: a previously undescribed entity</article-title><source>Neuropsychiatr Dis Treat</source><year>2015</year><volume>11</volume><fpage>2323</fpage><pub-id pub-id-type="doi">10.2147/NDT.S83350</pub-id><?supplied-pmid 26396516?><pub-id pub-id-type="pmid">26396516</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurtzke</surname><given-names>JF</given-names></name></person-group><article-title>Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)</article-title><source>Neurology</source><year>1983</year><volume>33</volume><fpage>1444</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1212/WNL.33.11.1444</pub-id><?supplied-pmid 6685237?><pub-id pub-id-type="pmid">6685237</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patrick</surname><given-names>E</given-names></name><name><surname>Christodoulou</surname><given-names>C</given-names></name><name><surname>Krupp</surname><given-names>L</given-names></name><collab>on behalf of the New York State MS Consortium</collab></person-group><article-title>Longitudinal correlates of fatigue in multiple sclerosis</article-title><source>Mult Scler</source><year>2008</year><volume>15</volume><issue>2</issue><fpage>258</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1177/1352458508097466</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Merkelbach</surname><given-names>S</given-names></name><name><surname>Schulz</surname><given-names>H</given-names></name><name><surname>K&#x000f6;lmel</surname><given-names>HW</given-names></name><name><surname>Gora</surname><given-names>G</given-names></name><name><surname>Klingelh&#x000f6;fer</surname><given-names>J</given-names></name><name><surname>Dachsel</surname><given-names>R</given-names></name><etal/></person-group><article-title>Fatigue, sleepiness, and physical activity in patients with multiple sclerosis</article-title><source>J Neurol</source><year>2011</year><volume>258</volume><issue>1</issue><fpage>74</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1007/s00415-010-5684-3</pub-id><?supplied-pmid 20714745?><pub-id pub-id-type="pmid">20714745</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colosimo</surname><given-names>C</given-names></name><name><surname>Millefiorini</surname><given-names>E</given-names></name><name><surname>Grasso</surname><given-names>MG</given-names></name><name><surname>Vinci</surname><given-names>F</given-names></name><name><surname>Fiorelli</surname><given-names>M</given-names></name><name><surname>Koudriavtseva</surname><given-names>T</given-names></name><etal/></person-group><article-title>Fatigue in MS is associated with specific clinical features</article-title><source>Acta Neurol Scand</source><year>1995</year><volume>92</volume><issue>5</issue><fpage>353</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0404.1995.tb00145.x</pub-id><?supplied-pmid 8610485?><pub-id pub-id-type="pmid">8610485</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mills</surname><given-names>RJ</given-names></name><name><surname>Young</surname><given-names>CA</given-names></name></person-group><article-title>The relationship between fatigue and other clinical features of multiple sclerosis</article-title><source>Mult Scler</source><year>2011</year><volume>17</volume><issue>5</issue><fpage>604</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1177/1352458510392262</pub-id><?supplied-pmid 21135018?><pub-id pub-id-type="pmid">21135018</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Runia</surname><given-names>TF</given-names></name><name><surname>Jafari</surname><given-names>N</given-names></name><name><surname>Siepman</surname><given-names>DAM</given-names></name><name><surname>Hintzen</surname><given-names>RQ</given-names></name></person-group><article-title>Fatigue at time of CIS is an independent predictor of a subsequent diagnosis of multiple sclerosis</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2015</year><volume>86</volume><issue>5</issue><fpage>543</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1136/jnnp-2014-308374</pub-id><?supplied-pmid 25053770?><pub-id pub-id-type="pmid">25053770</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marrie</surname><given-names>RA</given-names></name><name><surname>Reingold</surname><given-names>S</given-names></name><name><surname>Cohen</surname><given-names>J</given-names></name><name><surname>Stuve</surname><given-names>O</given-names></name><name><surname>Trojano</surname><given-names>M</given-names></name><name><surname>Sorensen</surname><given-names>PS</given-names></name><etal/></person-group><article-title>The incidence and prevalence of psychiatric disorders in multiple sclerosis: a systematic review</article-title><source>Mult Scler</source><year>2015</year><volume>21</volume><issue>3</issue><fpage>305</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1177/1352458514564487</pub-id><?supplied-pmid 25583845?><pub-id pub-id-type="pmid">25583845</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiaravalloti</surname><given-names>ND</given-names></name><name><surname>DeLuca</surname><given-names>J</given-names></name></person-group><article-title>Cognitive impairment in multiple sclerosis</article-title><source>Lancet Neurol</source><year>2008</year><volume>7</volume><issue>12</issue><fpage>1139</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(08)70259-X</pub-id><?supplied-pmid 19007738?><pub-id pub-id-type="pmid">19007738</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rao</surname><given-names>SM</given-names></name><name><surname>Leo</surname><given-names>GJ</given-names></name><name><surname>Bernardin</surname><given-names>L</given-names></name><name><surname>Unverzagt</surname><given-names>F</given-names></name></person-group><article-title>Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction</article-title><source>Neurology</source><year>1991</year><volume>41</volume><issue>5</issue><fpage>685</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1212/WNL.41.5.685</pub-id><?supplied-pmid 2027484?><pub-id pub-id-type="pmid">2027484</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Urbanek</surname><given-names>C</given-names></name><name><surname>Weinges-Evers</surname><given-names>N</given-names></name><name><surname>Bellmann-Strobl</surname><given-names>J</given-names></name><name><surname>Bock</surname><given-names>M</given-names></name><name><surname>D&#x000f6;rr</surname><given-names>J</given-names></name><name><surname>Hahn</surname><given-names>E</given-names></name><etal/></person-group><article-title>Attention Network Test reveals alerting network dysfunction in multiple sclerosis</article-title><source>Mult Scler</source><year>2010</year><volume>16</volume><issue>1</issue><fpage>93</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1177/1352458509350308</pub-id><?supplied-pmid 19995842?><pub-id pub-id-type="pmid">19995842</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeLuca</surname><given-names>J</given-names></name><name><surname>Johnson</surname><given-names>SK</given-names></name><name><surname>Natelson</surname><given-names>BH</given-names></name></person-group><article-title>Information processing efficiency in chronic fatigue syndrome and multiple sclerosis</article-title><source>Arch Neurol</source><year>1993</year><volume>50</volume><issue>3</issue><fpage>301</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1001/archneur.1993.00540030065016</pub-id><?supplied-pmid 8442710?><pub-id pub-id-type="pmid">8442710</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Demaree</surname><given-names>HA</given-names></name><name><surname>DeLuca</surname><given-names>J</given-names></name><name><surname>Gaudino</surname><given-names>EA</given-names></name><name><surname>Diamond</surname><given-names>BJ</given-names></name></person-group><article-title>Speed of information processing as a key deficit in multiple sclerosis: implications for rehabilitation</article-title><source>J Neurol Neurosurg Psychiatry</source><year>1999</year><volume>67</volume><issue>5</issue><fpage>661</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1136/jnnp.67.5.661</pub-id><?supplied-pmid 10519876?><pub-id pub-id-type="pmid">10519876</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCarthy</surname><given-names>M</given-names></name><name><surname>Beaumont</surname><given-names>JG</given-names></name><name><surname>Thompson</surname><given-names>R</given-names></name><name><surname>Peacock</surname><given-names>S</given-names></name></person-group><article-title>Modality-specific aspects of sustained and divided attentional performance in multiple sclerosis</article-title><source>Arch Clin Neuropsychol</source><year>2005</year><volume>20</volume><issue>6</issue><fpage>705</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1016/j.acn.2005.04.007</pub-id><?supplied-pmid 15913949?><pub-id pub-id-type="pmid">15913949</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weinges-Evers</surname><given-names>N</given-names></name><name><surname>Brandt</surname><given-names>AU</given-names></name><name><surname>Bock</surname><given-names>M</given-names></name><name><surname>Pfueller</surname><given-names>CF</given-names></name><name><surname>D&#x000f6;rr</surname><given-names>J</given-names></name><name><surname>Bellmann-Strobl</surname><given-names>J</given-names></name><etal/></person-group><article-title>Correlation of self-assessed fatigue and alertness in multiple sclerosis</article-title><source>Mult Scler</source><year>2010</year><volume>16</volume><issue>9</issue><fpage>1134</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1177/1352458510374202</pub-id><?supplied-pmid 20610494?><pub-id pub-id-type="pmid">20610494</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><mixed-citation publication-type="other">Guimar&#x000e3;es J, S&#x000e1; MJ. Cognitive dysfunction in multiple sclerosis. Front Neurol. 2012;3:74. doi:10.3389/fneur.2012.00074.&#x000a0;</mixed-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bellmann-Strobl</surname><given-names>J</given-names></name><name><surname>Wuerfel</surname><given-names>J</given-names></name><name><surname>Aktas</surname><given-names>O</given-names></name><name><surname>D&#x000f6;rr</surname><given-names>J</given-names></name><name><surname>Wernecke</surname><given-names>KD</given-names></name><name><surname>Zipp</surname><given-names>F</given-names></name><etal/></person-group><article-title>Poor PASAT performance correlates with MRI contrast enhancement in multiple sclerosis</article-title><source>Neurology</source><year>2009</year><volume>73</volume><issue>20</issue><fpage>1624</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e3181c1de4f</pub-id><?supplied-pmid 19917984?><pub-id pub-id-type="pmid">19917984</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>SK</given-names></name><name><surname>Lange</surname><given-names>G</given-names></name><name><surname>DeLuca</surname><given-names>J</given-names></name><name><surname>Korn</surname><given-names>LR</given-names></name><name><surname>Natelson</surname><given-names>B</given-names></name></person-group><article-title>The effects of fatigue on neuropsychological performance in patients with chronic fatigue syndrome, multiple sclerosis, and depression</article-title><source>Appl Neuropsychol</source><year>1997</year><volume>4</volume><issue>3</issue><fpage>145</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1207/s15324826an0403_1</pub-id><?supplied-pmid 16318477?><pub-id pub-id-type="pmid">16318477</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kujala</surname><given-names>P</given-names></name><name><surname>Portin</surname><given-names>R</given-names></name><name><surname>Revonsuo</surname><given-names>A</given-names></name><name><surname>Ruutiainen</surname><given-names>J</given-names></name></person-group><article-title>Attention related performance in two cognitively different subgroups of patients with multiple sclerosis</article-title><source>J Neurol Neurosurg Psychiatry</source><year>1995</year><volume>59</volume><fpage>77</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1136/jnnp.59.1.77</pub-id><?supplied-pmid 7608714?><pub-id pub-id-type="pmid">7608714</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krupp</surname><given-names>LB</given-names></name><name><surname>Elkins</surname><given-names>LE</given-names></name></person-group><article-title>Fatigue and declines in cognitive functioning in multiple sclerosis</article-title><source>Neurology</source><year>2000</year><volume>55</volume><issue>7</issue><fpage>934</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1212/WNL.55.7.934</pub-id><?supplied-pmid 11061247?><pub-id pub-id-type="pmid">11061247</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parmenter</surname><given-names>BA</given-names></name><name><surname>Denney</surname><given-names>DR</given-names></name><name><surname>Lynch</surname><given-names>SG</given-names></name></person-group><article-title>The cognitive performance of patients with multiple sclerosis during periods of high and low fatigue</article-title><source>Mult Scler</source><year>2003</year><volume>9</volume><issue>2</issue><fpage>111</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1191/1352458503ms859oa</pub-id><?supplied-pmid 12708805?><pub-id pub-id-type="pmid">12708805</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geisler</surname><given-names>MW</given-names></name><name><surname>Sliwinski</surname><given-names>M</given-names></name><name><surname>Coyle</surname><given-names>PK</given-names></name><name><surname>Masur</surname><given-names>DM</given-names></name><name><surname>Doscher</surname><given-names>C</given-names></name><name><surname>Krupp</surname><given-names>LB</given-names></name></person-group><article-title>The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis</article-title><source>Arch Neurol</source><year>1996</year><volume>53</volume><issue>2</issue><fpage>185</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1001/archneur.1996.00550020101021</pub-id><?supplied-pmid 8639070?><pub-id pub-id-type="pmid">8639070</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwartz</surname><given-names>CE</given-names></name><name><surname>Coulthard-Morris</surname><given-names>L</given-names></name><name><surname>Zeng</surname><given-names>Q</given-names></name></person-group><article-title>Psychosocial correlates of fatigue in multiple sclerosis</article-title><source>Arch Phys Med Rehabil</source><year>1996</year><volume>77</volume><issue>2</issue><fpage>165</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1016/S0003-9993(96)90162-8</pub-id><?supplied-pmid 8607741?><pub-id pub-id-type="pmid">8607741</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bailey</surname><given-names>A</given-names></name><name><surname>Channon</surname><given-names>S</given-names></name><name><surname>Beaumont</surname><given-names>JG</given-names></name></person-group><article-title>The relationship between subjective fatigue and cognitive fatigue in advanced multiple sclerosis</article-title><source>Mult Scler</source><year>2007</year><volume>13</volume><issue>1</issue><fpage>73</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1177/1352458506071162</pub-id><?supplied-pmid 17294614?><pub-id pub-id-type="pmid">17294614</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siegert</surname><given-names>RJ</given-names></name><name><surname>Abernethy</surname><given-names>DA</given-names></name></person-group><article-title>Depression in multiple sclerosis: a review</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2005</year><volume>76</volume><issue>4</issue><fpage>469</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1136/jnnp.2004.054635</pub-id><?supplied-pmid 15774430?><pub-id pub-id-type="pmid">15774430</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arnett</surname><given-names>PA</given-names></name><name><surname>Barwick</surname><given-names>FH</given-names></name><name><surname>Beeney</surname><given-names>JE</given-names></name></person-group><article-title>Depression in multiple sclerosis: review and theoretical proposal</article-title><source>J Int Neuropsychol Soc</source><year>2008</year><volume>14</volume><issue>5</issue><fpage>691</fpage><lpage>724</lpage><pub-id pub-id-type="doi">10.1017/S1355617708081174</pub-id><?supplied-pmid 18764967?><pub-id pub-id-type="pmid">18764967</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arnett</surname><given-names>PA</given-names></name><name><surname>Higginson</surname><given-names>CI</given-names></name><name><surname>Voss</surname><given-names>WD</given-names></name><name><surname>Wright</surname><given-names>B</given-names></name><name><surname>Bender</surname><given-names>WI</given-names></name><name><surname>Wurst</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Depressed mood in multiple sclerosis: relationship to capacity-demanding memory and attentional functioning</article-title><source>Neuropsychology</source><year>1999</year><volume>13</volume><issue>3</issue><fpage>434</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1037/0894-4105.13.3.434</pub-id><?supplied-pmid 10447304?><pub-id pub-id-type="pmid">10447304</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arnett</surname><given-names>PA</given-names></name><name><surname>Higginson</surname><given-names>CI</given-names></name><name><surname>Voss</surname><given-names>WD</given-names></name><name><surname>Bender</surname><given-names>WI</given-names></name><name><surname>Wurst</surname><given-names>JM</given-names></name><name><surname>Tippin</surname><given-names>JM</given-names></name></person-group><article-title>Depression in multiple sclerosis: relationship to working memory capacity</article-title><source>Neuropsychology</source><year>1999</year><volume>13</volume><issue>4</issue><fpage>546</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1037/0894-4105.13.4.546</pub-id><?supplied-pmid 10527063?><pub-id pub-id-type="pmid">10527063</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arnett</surname><given-names>PA</given-names></name><name><surname>Higginson</surname><given-names>CI</given-names></name><name><surname>Randolph</surname><given-names>JJ</given-names></name></person-group><article-title>Depression in multiple sclerosis: relationship to planning ability</article-title><source>J Int Neuropsychol Soc</source><year>2001</year><volume>7</volume><issue>6</issue><fpage>665</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1017/S1355617701766027</pub-id><?supplied-pmid 11575588?><pub-id pub-id-type="pmid">11575588</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diamond</surname><given-names>BJ</given-names></name><name><surname>Johnson</surname><given-names>SK</given-names></name><name><surname>Kaufman</surname><given-names>M</given-names></name><name><surname>Graves</surname><given-names>L</given-names></name></person-group><article-title>Relationships between information processing, depression, fatigue and cognition in multiple sclerosis</article-title><source>Arch Clin Neuropsychol</source><year>2008</year><volume>23</volume><issue>2</issue><fpage>189</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1016/j.acn.2007.10.002</pub-id><?supplied-pmid 18053682?><pub-id pub-id-type="pmid">18053682</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeLuca</surname><given-names>J</given-names></name><name><surname>Chelune</surname><given-names>GJ</given-names></name><name><surname>Tulsky</surname><given-names>DS</given-names></name><name><surname>Lengenfelder</surname><given-names>J</given-names></name><name><surname>Chiaravalloti</surname><given-names>ND</given-names></name></person-group><article-title>Is speed of processing or working memory the primary information processing deficit in multiple sclerosis?</article-title><source>J Clin Exp Neuropsychol</source><year>2004</year><volume>26</volume><issue>4</issue><fpage>550</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1080/13803390490496641</pub-id><?supplied-pmid 15512942?><pub-id pub-id-type="pmid">15512942</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Archibald</surname><given-names>CJ</given-names></name><name><surname>Fisk</surname><given-names>JD</given-names></name></person-group><article-title>Information processing efficiency in patients with multiple sclerosis</article-title><source>J Clin Exp Neuropsychol</source><year>2000</year><volume>22</volume><issue>5</issue><fpage>686</fpage><lpage>701</lpage><pub-id pub-id-type="doi">10.1076/1380-3395(200010)22:5;1-9;FT686</pub-id><?supplied-pmid 11094403?><pub-id pub-id-type="pmid">11094403</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaudino</surname><given-names>EA</given-names></name><name><surname>Chiaravalloti</surname><given-names>ND</given-names></name><name><surname>DeLuca</surname><given-names>J</given-names></name><name><surname>Diamond</surname><given-names>BJ</given-names></name></person-group><article-title>A comparison of memory performance in relapsing-remitting, primary progressive and secondary progressive, multiple sclerosis</article-title><source>Neuropsychiatry Neuropsychol Behav Neurol</source><year>2001</year><volume>14</volume><issue>1</issue><fpage>32</fpage><lpage>44</lpage><?supplied-pmid 11234907?><pub-id pub-id-type="pmid">11234907</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benedict</surname><given-names>RHB</given-names></name><name><surname>Cookfair</surname><given-names>D</given-names></name><name><surname>Gavett</surname><given-names>R</given-names></name><name><surname>Gunther</surname><given-names>M</given-names></name><name><surname>Munschauer</surname><given-names>F</given-names></name><name><surname>Garg</surname><given-names>N</given-names></name><etal/></person-group><article-title>Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS)</article-title><source>J Int Neuropsychol Soc</source><year>2006</year><volume>12</volume><issue>4</issue><fpage>549</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1017/S1355617706060723</pub-id><?supplied-pmid 16981607?><pub-id pub-id-type="pmid">16981607</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langdon</surname><given-names>D</given-names></name><name><surname>Amato</surname><given-names>M</given-names></name><name><surname>Boringa</surname><given-names>J</given-names></name><name><surname>Brochet</surname><given-names>B</given-names></name><name><surname>Foley</surname><given-names>F</given-names></name><name><surname>Fredrikson</surname><given-names>S</given-names></name><etal/></person-group><article-title>Recommendations for a Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)</article-title><source>Mult Scler</source><year>2012</year><volume>18</volume><issue>6</issue><fpage>891</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1177/1352458511431076</pub-id><?supplied-pmid 22190573?><pub-id pub-id-type="pmid">22190573</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaminska</surname><given-names>M</given-names></name><name><surname>Kimoff</surname><given-names>R</given-names></name><name><surname>Benedetti</surname><given-names>A</given-names></name><name><surname>Robinson</surname><given-names>A</given-names></name><name><surname>Bar-Or</surname><given-names>A</given-names></name><name><surname>Lapierre</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Obstructive sleep apnea is associated with fatigue in multiple sclerosis</article-title><source>Mult Scler</source><year>2012</year><volume>18</volume><issue>8</issue><fpage>1159</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1177/1352458511432328</pub-id><?supplied-pmid 22183937?><pub-id pub-id-type="pmid">22183937</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veauthier</surname><given-names>C</given-names></name><name><surname>Gaede</surname><given-names>G</given-names></name><name><surname>Radbruch</surname><given-names>H</given-names></name><name><surname>Gottschalk</surname><given-names>S</given-names></name><name><surname>Wernecke</surname><given-names>K-D</given-names></name><name><surname>Paul</surname><given-names>F</given-names></name></person-group><article-title>Treatment of sleep disorders may improve fatigue in multiple sclerosis</article-title><source>Clin Neurol Neurosurg</source><year>2013</year><volume>115</volume><issue>9</issue><fpage>1826</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1016/j.clineuro.2013.05.018</pub-id><?supplied-pmid 23764040?><pub-id pub-id-type="pmid">23764040</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cote</surname><given-names>I</given-names></name><name><surname>Trojan</surname><given-names>D</given-names></name><name><surname>Kaminska</surname><given-names>M</given-names></name><name><surname>Cardoso</surname><given-names>M</given-names></name><name><surname>Benedetti</surname><given-names>A</given-names></name><name><surname>Weiss</surname><given-names>D</given-names></name><etal/></person-group><article-title>Impact of sleep disorder treatment on fatigue in multiple sclerosis</article-title><source>Mult Scler</source><year>2013</year><volume>19</volume><issue>4</issue><fpage>480</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1177/1352458512455958</pub-id><?supplied-pmid 22914848?><pub-id pub-id-type="pmid">22914848</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braley</surname><given-names>TJ</given-names></name><name><surname>Segal</surname><given-names>BM</given-names></name><name><surname>Chervin</surname><given-names>RD</given-names></name></person-group><article-title>Hypnotic use and fatigue in multiple sclerosis</article-title><source>Sleep Med</source><year>2015</year><volume>16</volume><issue>1</issue><fpage>131</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.sleep.2014.09.006</pub-id><?supplied-pmid 25454981?><pub-id pub-id-type="pmid">25454981</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veauthier</surname><given-names>C</given-names></name></person-group><article-title>Hypnotic use and multiple sclerosis related fatigue: a forgotten confounder</article-title><source>Sleep Med</source><year>2015</year><volume>16</volume><issue>3</issue><fpage>319</fpage><pub-id pub-id-type="doi">10.1016/j.sleep.2014.11.012</pub-id><?supplied-pmid 25660815?><pub-id pub-id-type="pmid">25660815</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baglioni</surname><given-names>C</given-names></name><name><surname>Spiegelhalder</surname><given-names>K</given-names></name><name><surname>Nissen</surname><given-names>C</given-names></name><name><surname>Riemann</surname><given-names>D</given-names></name></person-group><article-title>Clinical implications of the causal relationship between insomnia and depression: how individually tailored treatment of sleeping difficulties could prevent the onset of depression</article-title><source>EPMA J</source><year>2011</year><volume>2</volume><issue>3</issue><fpage>287</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1007/s13167-011-0079-9</pub-id><?supplied-pmid 23199164?><pub-id pub-id-type="pmid">23199164</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manconi</surname><given-names>M</given-names></name><name><surname>Ferini-Strambi</surname><given-names>L</given-names></name><name><surname>Filippi</surname><given-names>M</given-names></name><name><surname>Bonanni</surname><given-names>E</given-names></name><name><surname>Iudice</surname><given-names>A</given-names></name><name><surname>Murri</surname><given-names>L</given-names></name><etal/></person-group><article-title>Multicenter case-control study on restless legs syndrome in multiple sclerosis: the REMS study</article-title><source>Sleep</source><year>2008</year><volume>31</volume><issue>7</issue><fpage>944</fpage><lpage>52</lpage><?supplied-pmid 18655317?><pub-id pub-id-type="pmid">18655317</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Munger</surname><given-names>KL</given-names></name><name><surname>Batool-Anwar</surname><given-names>S</given-names></name><name><surname>De Vito</surname><given-names>K</given-names></name><name><surname>Ascherio</surname><given-names>A</given-names></name><name><surname>Gao</surname><given-names>X</given-names></name></person-group><article-title>Association of multiple sclerosis with restless legs syndrome and other sleep disorders in women</article-title><source>Neurology</source><year>2012</year><volume>78</volume><issue>19</issue><fpage>1500</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e3182553c5b</pub-id><?supplied-pmid 22539566?><pub-id pub-id-type="pmid">22539566</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braley</surname><given-names>TJ</given-names></name><name><surname>Segal</surname><given-names>BM</given-names></name><name><surname>Chervin</surname><given-names>RD</given-names></name></person-group><article-title>Sleep-disordered breathing in multiple sclerosis</article-title><source>Neurology</source><year>2012</year><volume>79</volume><issue>9</issue><fpage>929</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e318266fa9d</pub-id><?supplied-pmid 22895593?><pub-id pub-id-type="pmid">22895593</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Habukawa</surname><given-names>M</given-names></name><name><surname>Uchimura</surname><given-names>N</given-names></name><name><surname>Kakuma</surname><given-names>T</given-names></name><name><surname>Yamamoto</surname><given-names>K</given-names></name><name><surname>Ogi</surname><given-names>K</given-names></name><name><surname>Hiejima</surname><given-names>H</given-names></name><etal/></person-group><article-title>Effect of CPAP treatment on residual depressive symptoms in patients with major depression and coexisting sleep apnea: contribution of daytime sleepiness to residual depressive symptoms</article-title><source>Sleep Med</source><year>2010</year><volume>11</volume><issue>6</issue><fpage>552</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.sleep.2010.02.007</pub-id><?supplied-pmid 20488748?><pub-id pub-id-type="pmid">20488748</pub-id></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwartz</surname><given-names>DJ</given-names></name><name><surname>Karatinos</surname><given-names>G</given-names></name></person-group><article-title>For individuals with obstructive sleep apnea, institution of CPAP therapy is associated with an amelioration of symptoms of depression which is sustained long term</article-title><source>J Clin Sleep Med</source><year>2007</year><volume>3</volume><issue>6</issue><fpage>631</fpage><lpage>5</lpage><?supplied-pmid 17993046?><pub-id pub-id-type="pmid">17993046</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hasselmann</surname><given-names>H</given-names></name><name><surname>Bellmann-Strobl</surname><given-names>J</given-names></name><name><surname>Ricken</surname><given-names>R</given-names></name><name><surname>Oberwahrenbrock</surname><given-names>T</given-names></name><name><surname>Rose</surname><given-names>M</given-names></name><name><surname>Otte</surname><given-names>C</given-names></name><etal/></person-group><article-title>Characterizing the phenotype of multiple sclerosis-associated depression in comparison with idiopathic major depression</article-title><source>Mult Scler</source><year>2016</year><volume>22</volume><issue>11</issue><fpage>1476</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1177/1352458515622826</pub-id><?supplied-pmid 26746809?><pub-id pub-id-type="pmid">26746809</pub-id></element-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahajan</surname><given-names>ST</given-names></name><name><surname>Patel</surname><given-names>PB</given-names></name><name><surname>Marrie</surname><given-names>RA</given-names></name></person-group><article-title>Under treatment of overactive bladder symptoms in patients with multiple sclerosis: an ancillary analysis of the NARCOMS patient registry</article-title><source>J Urol</source><year>2010</year><volume>183</volume><issue>4</issue><fpage>1432</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.juro.2009.12.029</pub-id><?supplied-pmid 20171697?><pub-id pub-id-type="pmid">20171697</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buysse</surname><given-names>DJ</given-names></name><name><surname>Reynolds</surname><given-names>CF</given-names></name><name><surname>Monk</surname><given-names>TH</given-names></name><name><surname>Berman</surname><given-names>SR</given-names></name><name><surname>Kupfer</surname><given-names>DJ</given-names></name></person-group><article-title>The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research</article-title><source>Psychiatry Res</source><year>1989</year><volume>28</volume><issue>2</issue><fpage>193</fpage><lpage>213</lpage><pub-id pub-id-type="doi">10.1016/0165-1781(89)90047-4</pub-id><?supplied-pmid 2748771?><pub-id pub-id-type="pmid">2748771</pub-id></element-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veauthier</surname><given-names>C</given-names></name><name><surname>Paul</surname><given-names>F</given-names></name></person-group><article-title>Fatigue in multiple sclerosis: which patient should be referred to a sleep specialist?</article-title><source>Mult Scler</source><year>2012</year><volume>18</volume><issue>2</issue><fpage>248</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1177/1352458511411229</pub-id><?supplied-pmid 21652611?><pub-id pub-id-type="pmid">21652611</pub-id></element-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sinnecker</surname><given-names>T</given-names></name><name><surname>Mittelstaedt</surname><given-names>P</given-names></name><name><surname>D&#x000f6;rr</surname><given-names>J</given-names></name><name><surname>Pfueller</surname><given-names>CF</given-names></name><name><surname>Harms</surname><given-names>L</given-names></name><name><surname>Niendorf</surname><given-names>T</given-names></name><etal/></person-group><article-title>Multiple sclerosis lesions and irreversible brain tissue damage: a comparative ultrahigh-field strength magnetic resonance imaging study</article-title><source>Arch Neurol</source><year>2012</year><volume>69</volume><issue>6</issue><fpage>739</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1001/archneurol.2011.2450</pub-id><?supplied-pmid 22351849?><pub-id pub-id-type="pmid">22351849</pub-id></element-citation></ref><ref id="CR84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bakshi</surname><given-names>R</given-names></name><name><surname>Yeste</surname><given-names>A</given-names></name><name><surname>Patel</surname><given-names>B</given-names></name><name><surname>Tauhid</surname><given-names>S</given-names></name><name><surname>Tummala</surname><given-names>S</given-names></name><name><surname>Rahbari</surname><given-names>R</given-names></name><etal/></person-group><article-title>Serum lipid antibodies are associated with cerebral tissue damage in multiple sclerosis</article-title><source>Neurol Neuroimmunol Neuroinflamm</source><year>2016</year><volume>3</volume><issue>2</issue><fpage>e200</fpage><pub-id pub-id-type="doi">10.1212/NXI.0000000000000200</pub-id><?supplied-pmid 26894204?><pub-id pub-id-type="pmid">26894204</pub-id></element-citation></ref><ref id="CR85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Azevedo</surname><given-names>CJ</given-names></name><name><surname>Overton</surname><given-names>E</given-names></name><name><surname>Khadka</surname><given-names>S</given-names></name><name><surname>Buckley</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Sampat</surname><given-names>M</given-names></name><etal/></person-group><article-title>Early CNS neurodegeneration in radiologically isolated syndrome</article-title><source>Neurol Neuroimmunol Neuroinflamm</source><year>2015</year><volume>2</volume><issue>3</issue><fpage>e102</fpage><pub-id pub-id-type="doi">10.1212/NXI.0000000000000102</pub-id><?supplied-pmid 25884012?><pub-id pub-id-type="pmid">25884012</pub-id></element-citation></ref><ref id="CR86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zivadinov</surname><given-names>R</given-names></name><name><surname>Cerza</surname><given-names>N</given-names></name><name><surname>Hagemeier</surname><given-names>J</given-names></name><name><surname>Carl</surname><given-names>E</given-names></name><name><surname>Badgett</surname><given-names>D</given-names></name><name><surname>Ramasamy</surname><given-names>DP</given-names></name><etal/></person-group><article-title>Humoral response to EBV is associated with cortical atrophy and lesion burden in patients with MS</article-title><source>Neurol Neuroimmunol Neuroinflamm</source><year>2016</year><volume>3</volume><issue>1</issue><fpage>e190</fpage><pub-id pub-id-type="doi">10.1212/NXI.0000000000000190</pub-id><?supplied-pmid 26770996?><pub-id pub-id-type="pmid">26770996</pub-id></element-citation></ref><ref id="CR87"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>P&#x000e9;rez-Miralles</surname><given-names>FC</given-names></name><name><surname>Sastre-Garriga</surname><given-names>J</given-names></name><name><surname>Vidal-Jordana</surname><given-names>A</given-names></name><name><surname>R&#x000ed;o</surname><given-names>J</given-names></name><name><surname>Auger</surname><given-names>C</given-names></name><name><surname>Pareto</surname><given-names>D</given-names></name><etal/></person-group><article-title>Predictive value of early brain atrophy on response in patients treated with interferon &#x003b2;</article-title><source>Neurol Neuroimmunol Neuroinflamm</source><year>2015</year><volume>2</volume><issue>4</issue><fpage>e132</fpage><pub-id pub-id-type="doi">10.1212/NXI.0000000000000132</pub-id><?supplied-pmid 26185778?><pub-id pub-id-type="pmid">26185778</pub-id></element-citation></ref><ref id="CR88"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paul</surname><given-names>F</given-names></name></person-group><article-title>Pathology and MRI: exploring cognitive impairment in MS</article-title><source>Acta Neurol Scand</source><year>2016</year><volume>134</volume><issue>Suppl 200</issue><fpage>24</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1111/ane.12649</pub-id><?supplied-pmid 27580903?><pub-id pub-id-type="pmid">27580903</pub-id></element-citation></ref><ref id="CR89"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tartaglia</surname><given-names>MC</given-names></name><name><surname>Narayanan</surname><given-names>S</given-names></name><name><surname>Francis</surname><given-names>SJ</given-names></name><name><surname>Santos</surname><given-names>AC</given-names></name><name><surname>De Stefano</surname><given-names>N</given-names></name><name><surname>Lapierre</surname><given-names>Y</given-names></name><etal/></person-group><article-title>The relationship between diffuse axonal damage and fatigue in multiple sclerosis</article-title><source>Arch Neurol</source><year>2004</year><volume>61</volume><issue>2</issue><fpage>201</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1001/archneur.61.2.201</pub-id><?supplied-pmid 14967766?><pub-id pub-id-type="pmid">14967766</pub-id></element-citation></ref><ref id="CR90"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calabrese</surname><given-names>M</given-names></name><name><surname>Rinaldi</surname><given-names>F</given-names></name><name><surname>Grossi</surname><given-names>P</given-names></name><name><surname>Mattisi</surname><given-names>I</given-names></name><name><surname>Bernardi</surname><given-names>V</given-names></name><name><surname>Favaretto</surname><given-names>A</given-names></name><etal/></person-group><article-title>Basal ganglia and frontal/parietal cortical atrophy is associated with fatigue in relapsing-remitting multiple sclerosis</article-title><source>Mult Scler</source><year>2010</year><volume>16</volume><issue>10</issue><fpage>1220</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1177/1352458510376405</pub-id><?supplied-pmid 20670981?><pub-id pub-id-type="pmid">20670981</pub-id></element-citation></ref><ref id="CR91"><label>91.</label><mixed-citation publication-type="other">Pellicano C, Gallo A, Li X, Ikonomidou VN, Evangelou IE, Ohayon JM, et al. Relationship of cortical atrophy to fatigue in patients with multiple sclerosis. Arch Neurol. 2010;67(4).</mixed-citation></ref><ref id="CR92"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yaldizli</surname><given-names>O</given-names></name><name><surname>Penner</surname><given-names>I-K</given-names></name><name><surname>Frontzek</surname><given-names>K</given-names></name><name><surname>Naegelin</surname><given-names>Y</given-names></name><name><surname>Amann</surname><given-names>M</given-names></name><name><surname>Papadopoulou</surname><given-names>A</given-names></name><etal/></person-group><article-title>The relationship between total and regional corpus callosum atrophy, cognitive impairment and fatigue in multiple sclerosis patients</article-title><source>Mult Scler</source><year>2014</year><volume>20</volume><issue>3</issue><fpage>356</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1177/1352458513496880</pub-id><?supplied-pmid 23959709?><pub-id pub-id-type="pmid">23959709</pub-id></element-citation></ref><ref id="CR93"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nygaard</surname><given-names>GO</given-names></name><name><surname>Walhovd</surname><given-names>KB</given-names></name><name><surname>Sowa</surname><given-names>P</given-names></name><name><surname>Chepkoech</surname><given-names>J-L</given-names></name><name><surname>Bjornerud</surname><given-names>A</given-names></name><name><surname>Due-Tonnessen</surname><given-names>P</given-names></name><etal/></person-group><article-title>Cortical thickness and surface area relate to specific symptoms in early relapsing-remitting multiple sclerosis</article-title><source>Mult Scler</source><year>2015</year><volume>21</volume><issue>4</issue><fpage>402</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1177/1352458514543811</pub-id><?supplied-pmid 25139946?><pub-id pub-id-type="pmid">25139946</pub-id></element-citation></ref><ref id="CR94"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gobbi</surname><given-names>C</given-names></name><name><surname>Rocca</surname><given-names>M</given-names></name><name><surname>Riccitelli</surname><given-names>G</given-names></name><name><surname>Pagani</surname><given-names>E</given-names></name><name><surname>Messina</surname><given-names>R</given-names></name><name><surname>Preziosa</surname><given-names>P</given-names></name><etal/></person-group><article-title>Influence of the topography of brain damage on depression and fatigue in patients with multiple sclerosis</article-title><source>Mult Scler</source><year>2014</year><volume>20</volume><issue>2</issue><fpage>192</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.1177/1352458513493684</pub-id><?supplied-pmid 23812284?><pub-id pub-id-type="pmid">23812284</pub-id></element-citation></ref><ref id="CR95"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sepulcre</surname><given-names>J</given-names></name><name><surname>Masdeu</surname><given-names>J</given-names></name><name><surname>Goni</surname><given-names>J</given-names></name><name><surname>Arrondo</surname><given-names>G</given-names></name><name><surname>Velez de Mendizabal</surname><given-names>N</given-names></name><name><surname>Bejarano</surname><given-names>B</given-names></name><etal/></person-group><article-title>Fatigue in multiple sclerosis is associated with the disruption of frontal and parietal pathways</article-title><source>Mult Scler</source><year>2009</year><volume>15</volume><issue>3</issue><fpage>337</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1177/1352458508098373</pub-id><?supplied-pmid 18987107?><pub-id pub-id-type="pmid">18987107</pub-id></element-citation></ref><ref id="CR96"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Damasceno</surname><given-names>A</given-names></name><name><surname>Damasceno</surname><given-names>BP</given-names></name><name><surname>Cendes</surname><given-names>F</given-names></name></person-group><article-title>Atrophy of reward-related striatal structures in fatigued MS patients is independent of physical disability</article-title><source>Mult Scler</source><year>2016</year><volume>22</volume><issue>6</issue><fpage>822</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1177/1352458515599451</pub-id><?supplied-pmid 26238465?><pub-id pub-id-type="pmid">26238465</pub-id></element-citation></ref><ref id="CR97"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roelcke</surname><given-names>U</given-names></name><name><surname>Kappos</surname><given-names>L</given-names></name><name><surname>Lechner-Scott</surname><given-names>J</given-names></name><name><surname>Brunnschweiler</surname><given-names>H</given-names></name><name><surname>Huber</surname><given-names>S</given-names></name><name><surname>Ammann</surname><given-names>W</given-names></name><etal/></person-group><article-title>Reduced glucose metabolism in the frontal cortex and basal ganglia of multiple sclerosis patients with fatigue: a 18F-fluorodeoxyglucose positron emission tomography study</article-title><source>Neurology</source><year>1997</year><volume>48</volume><issue>6</issue><fpage>1566</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1212/WNL.48.6.1566</pub-id><?supplied-pmid 9191767?><pub-id pub-id-type="pmid">9191767</pub-id></element-citation></ref><ref id="CR98"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finke</surname><given-names>C</given-names></name><name><surname>Schlichting</surname><given-names>J</given-names></name><name><surname>Papazoglou</surname><given-names>S</given-names></name><name><surname>Scheel</surname><given-names>M</given-names></name><name><surname>Freing</surname><given-names>A</given-names></name><name><surname>Soemmer</surname><given-names>C</given-names></name><etal/></person-group><article-title>Altered basal ganglia functional connectivity in multiple sclerosis patients with fatigue</article-title><source>Mult Scler</source><year>2015</year><volume>21</volume><issue>7</issue><fpage>925</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1177/1352458514555784</pub-id><?supplied-pmid 25392321?><pub-id pub-id-type="pmid">25392321</pub-id></element-citation></ref><ref id="CR99"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rocca</surname><given-names>MA</given-names></name><name><surname>Meani</surname><given-names>A</given-names></name><name><surname>Riccitelli</surname><given-names>GC</given-names></name><name><surname>Colombo</surname><given-names>B</given-names></name><name><surname>Rodegher</surname><given-names>M</given-names></name><name><surname>Falini</surname><given-names>A</given-names></name><etal/></person-group><article-title>Abnormal adaptation over time of motor network recruitment in multiple sclerosis patients with fatigue</article-title><source>Mult Scler</source><year>2016</year><volume>22</volume><issue>9</issue><fpage>1144</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1177/1352458515614407</pub-id><?supplied-pmid 26493126?><pub-id pub-id-type="pmid">26493126</pub-id></element-citation></ref><ref id="CR100"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dantzer</surname><given-names>R</given-names></name><name><surname>O&#x02019;Connor</surname><given-names>JC</given-names></name><name><surname>Freund</surname><given-names>GG</given-names></name><name><surname>Johnson</surname><given-names>RW</given-names></name><name><surname>Kelley</surname><given-names>KW</given-names></name></person-group><article-title>From inflammation to sickness and depression: when the immune system subjugates the brain</article-title><source>Nat Rev Neurosci</source><year>2008</year><volume>9</volume><fpage>46</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1038/nrn2297</pub-id><?supplied-pmid 18073775?><pub-id pub-id-type="pmid">18073775</pub-id></element-citation></ref><ref id="CR101"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schedlowski</surname><given-names>M</given-names></name><name><surname>Engler</surname><given-names>H</given-names></name><name><surname>Grigoleit</surname><given-names>J-S</given-names></name></person-group><article-title>Endotoxin-induced experimental systemic inflammation in humans: a model to disentangle immune-to-brain communication</article-title><source>Brain Behav Immun</source><year>2014</year><volume>35</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.bbi.2013.09.015</pub-id><?supplied-pmid 24491305?><pub-id pub-id-type="pmid">24491305</pub-id></element-citation></ref><ref id="CR102"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>JG</given-names></name><name><surname>Park</surname><given-names>JW</given-names></name><name><surname>Koch</surname><given-names>M</given-names></name><name><surname>Horvath</surname><given-names>TL</given-names></name><name><surname>Lee</surname><given-names>BJ</given-names></name></person-group><article-title>Hypothalamic TLR2 triggers sickness behavior via a microglia-neuronal axis</article-title><source>Sci Rep</source><year>2016</year><volume>6</volume><fpage>29424</fpage><pub-id pub-id-type="doi">10.1038/srep29424</pub-id><?supplied-pmid 27405276?><pub-id pub-id-type="pmid">27405276</pub-id></element-citation></ref><ref id="CR103"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanken</surname><given-names>K</given-names></name><name><surname>Eling</surname><given-names>P</given-names></name><name><surname>Kastrup</surname><given-names>A</given-names></name><name><surname>Klein</surname><given-names>J</given-names></name><name><surname>Hildebrandt</surname><given-names>H</given-names></name></person-group><article-title>Integrity of hypothalamic fibers and cognitive fatigue in multiple sclerosis</article-title><source>Mult Scler Relat Disord</source><year>2015</year><volume>4</volume><issue>1</issue><fpage>39</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1016/j.msard.2014.11.006</pub-id><?supplied-pmid 25787051?><pub-id pub-id-type="pmid">25787051</pub-id></element-citation></ref><ref id="CR104"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giovannoni</surname><given-names>G</given-names></name><name><surname>Thompson</surname><given-names>AJ</given-names></name><name><surname>Miller</surname><given-names>DH</given-names></name><name><surname>Thompson</surname><given-names>EJ</given-names></name></person-group><article-title>Fatigue is not associated with raised inflammatory markers in multiple sclerosis</article-title><source>Neurology</source><year>2001</year><volume>57</volume><issue>4</issue><fpage>676</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1212/WNL.57.4.676</pub-id><?supplied-pmid 11524478?><pub-id pub-id-type="pmid">11524478</pub-id></element-citation></ref><ref id="CR105"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rudick</surname><given-names>RA</given-names></name><name><surname>Barna</surname><given-names>BP</given-names></name></person-group><article-title>Serum interleukin 2 and soluble interleukin 2 receptor in patients with multiple sclerosis who are experiencing severe fatigue</article-title><source>Arch Neurol</source><year>1990</year><volume>47</volume><issue>3</issue><fpage>254</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1001/archneur.1990.00530030018008</pub-id><?supplied-pmid 2310309?><pub-id pub-id-type="pmid">2310309</pub-id></element-citation></ref><ref id="CR106"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flachenecker</surname><given-names>P</given-names></name><name><surname>Bihler</surname><given-names>I</given-names></name><name><surname>Weber</surname><given-names>F</given-names></name><name><surname>Gottschalk</surname><given-names>M</given-names></name><name><surname>Toyka</surname><given-names>KV</given-names></name><name><surname>Rieckmann</surname><given-names>P</given-names></name></person-group><article-title>Cytokine mRNA expression in patients with multiple sclerosis and fatigue</article-title><source>Mult Scler</source><year>2004</year><volume>10</volume><issue>2</issue><fpage>165</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1191/1352458504ms991oa</pub-id><?supplied-pmid 15124762?><pub-id pub-id-type="pmid">15124762</pub-id></element-citation></ref><ref id="CR107"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heesen</surname><given-names>C</given-names></name><name><surname>Nawrath</surname><given-names>L</given-names></name><name><surname>Reich</surname><given-names>C</given-names></name><name><surname>Bauer</surname><given-names>N</given-names></name><name><surname>Schulz</surname><given-names>K-H</given-names></name><name><surname>Gold</surname><given-names>SM</given-names></name></person-group><article-title>Fatigue in multiple sclerosis: an example of cytokine mediated sickness behaviour?</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2006</year><volume>77</volume><issue>1</issue><fpage>34</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1136/jnnp.2005.065805</pub-id><?supplied-pmid 16361589?><pub-id pub-id-type="pmid">16361589</pub-id></element-citation></ref><ref id="CR108"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gold</surname><given-names>SM</given-names></name><name><surname>Kr&#x000fc;ger</surname><given-names>S</given-names></name><name><surname>Ziegler</surname><given-names>KJ</given-names></name><name><surname>Krieger</surname><given-names>T</given-names></name><name><surname>Schulz</surname><given-names>K-H</given-names></name><name><surname>Otte</surname><given-names>C</given-names></name><etal/></person-group><article-title>Endocrine and immune substrates of depressive symptoms and fatigue in multiple sclerosis patients with comorbid major depression</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2011</year><volume>82</volume><issue>7</issue><fpage>814</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1136/jnnp.2010.230029</pub-id><?supplied-pmid 21296901?><pub-id pub-id-type="pmid">21296901</pub-id></element-citation></ref><ref id="CR109"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malekzadeh</surname><given-names>A</given-names></name><name><surname>Van de Geer-Peeters</surname><given-names>W</given-names></name><name><surname>De Groot</surname><given-names>V</given-names></name><name><surname>Teunissen</surname><given-names>CE</given-names></name><name><surname>Beckerman</surname><given-names>H</given-names></name><collab>TREFAMS-ACE Study Group</collab></person-group><article-title>Fatigue in patients with multiple sclerosis: is it related to pro- and anti-inflammatory cytokines?</article-title><source>Dis Markers</source><year>2015</year><volume>2015</volume><fpage>758314</fpage><pub-id pub-id-type="doi">10.1155/2015/758314</pub-id><?supplied-pmid 25722532?><pub-id pub-id-type="pmid">25722532</pub-id></element-citation></ref><ref id="CR110"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gottschalk</surname><given-names>M</given-names></name><name><surname>K&#x000fc;mpfel</surname><given-names>T</given-names></name><name><surname>Flachenecker</surname><given-names>P</given-names></name><name><surname>Uhr</surname><given-names>M</given-names></name><name><surname>Trenkwalder</surname><given-names>C</given-names></name><name><surname>Holsboer</surname><given-names>F</given-names></name><etal/></person-group><article-title>Fatigue and regulation of the hypothalamo-pituitary-adrenal axis in multiple sclerosis</article-title><source>Arch Neurol</source><year>2005</year><volume>62</volume><issue>2</issue><fpage>277</fpage><pub-id pub-id-type="doi">10.1001/archneur.62.2.277</pub-id><?supplied-pmid 15710856?><pub-id pub-id-type="pmid">15710856</pub-id></element-citation></ref><ref id="CR111"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>T&#x000e9;llez</surname><given-names>N</given-names></name><name><surname>Comabella</surname><given-names>M</given-names></name><name><surname>Juli&#x000e0;</surname><given-names>E</given-names></name><name><surname>R&#x000ed;o</surname><given-names>J</given-names></name><name><surname>Tintor&#x000e9;</surname><given-names>M</given-names></name><name><surname>Brieva</surname><given-names>L</given-names></name><etal/></person-group><article-title>Fatigue in progressive multiple sclerosis is associated with low levels of dehydroepiandrosterone</article-title><source>Mult Scler</source><year>2006</year><volume>12</volume><issue>4</issue><fpage>487</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1191/135248505ms1322oa</pub-id><?supplied-pmid 16900763?><pub-id pub-id-type="pmid">16900763</pub-id></element-citation></ref><ref id="CR112"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Powell</surname><given-names>DJH</given-names></name><name><surname>Moss-Morris</surname><given-names>R</given-names></name><name><surname>Liossi</surname><given-names>C</given-names></name><name><surname>Schlotz</surname><given-names>W</given-names></name></person-group><article-title>Circadian cortisol and fatigue severity in relapsing-remitting multiple sclerosis</article-title><source>Psychoneuroendocrinology</source><year>2015</year><volume>56</volume><fpage>120</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1016/j.psyneuen.2015.03.010</pub-id><?supplied-pmid 25817406?><pub-id pub-id-type="pmid">25817406</pub-id></element-citation></ref><ref id="CR113"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jongen</surname><given-names>PJ</given-names></name><name><surname>Lehnick</surname><given-names>D</given-names></name><name><surname>Koeman</surname><given-names>J</given-names></name><name><surname>Frequin</surname><given-names>S</given-names></name><name><surname>Heersema</surname><given-names>D</given-names></name><name><surname>Kornips</surname><given-names>B</given-names></name><etal/></person-group><article-title>Fatigue and health-related quality of life in relapsing-remitting multiple sclerosis after 2&#x000a0;years glatiramer acetate treatment are predicted by changes at 6&#x000a0;months: an observational multi-center study</article-title><source>J Neurol</source><year>2014</year><volume>261</volume><issue>8</issue><fpage>1469</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1007/s00415-014-7363-2</pub-id><?supplied-pmid 24792727?><pub-id pub-id-type="pmid">24792727</pub-id></element-citation></ref><ref id="CR114"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Melanson</surname><given-names>M</given-names></name><name><surname>Grossberndt</surname><given-names>A</given-names></name><name><surname>Klowak</surname><given-names>M</given-names></name><name><surname>Leong</surname><given-names>C</given-names></name><name><surname>Frost</surname><given-names>EE</given-names></name><name><surname>Prout</surname><given-names>M</given-names></name><etal/></person-group><article-title>Fatigue and cognition in patients with relapsing multiple sclerosis treated with interferon beta</article-title><source>Int J Neurosci</source><year>2010</year><volume>120</volume><issue>10</issue><fpage>631</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.3109/00207454.2010.511732</pub-id><?supplied-pmid 20942577?><pub-id pub-id-type="pmid">20942577</pub-id></element-citation></ref><ref id="CR115"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ziemssen</surname><given-names>T</given-names></name></person-group><article-title>Multiple sclerosis beyond EDSS: depression and fatigue</article-title><source>J Neurol Sci</source><year>2009</year><volume>277</volume><fpage>S37</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1016/S0022-510X(09)70011-5</pub-id><?supplied-pmid 19200865?><pub-id pub-id-type="pmid">19200865</pub-id></element-citation></ref><ref id="CR116"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patti</surname><given-names>F</given-names></name><name><surname>Amato</surname><given-names>MP</given-names></name><name><surname>Trojano</surname><given-names>M</given-names></name><name><surname>Bastianello</surname><given-names>S</given-names></name><name><surname>Tola</surname><given-names>MR</given-names></name><name><surname>Picconi</surname><given-names>O</given-names></name><etal/></person-group><article-title>Quality of life, depression and fatigue in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: 3-year results from the COGIMUS (COGnitive Impairment in MUltiple Sclerosis) study</article-title><source>Mult Scler</source><year>2011</year><volume>17</volume><issue>8</issue><fpage>991</fpage><lpage>1001</lpage><pub-id pub-id-type="doi">10.1177/1352458511401943</pub-id><?supplied-pmid 21502310?><pub-id pub-id-type="pmid">21502310</pub-id></element-citation></ref><ref id="CR117"><label>117.</label><mixed-citation publication-type="other">Kunkel A, Fischer M, Faiss J, D&#x000e4;hne D, K&#x000f6;hler W, Faiss JH. Impact of natalizumab treatment on fatigue, mood, and aspects of cognition in relapsing-remitting multiple sclerosis. Front Neurol. 2015;6:97. doi:10.3389/fneur.2015.00097. eCollection 2015.</mixed-citation></ref><ref id="CR118"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Penner</surname><given-names>I-K</given-names></name><name><surname>Sivertsdotter</surname><given-names>EC</given-names></name><name><surname>Celius</surname><given-names>EG</given-names></name><name><surname>Fuchs</surname><given-names>S</given-names></name><name><surname>Schreiber</surname><given-names>K</given-names></name><name><surname>Berk&#x000f6;</surname><given-names>S</given-names></name><etal/></person-group><article-title>Improvement in fatigue during natalizumab treatment is linked to improvement in depression and day-time sleepiness</article-title><source>Front Neurol</source><year>2015</year><volume>6</volume><fpage>18</fpage><?supplied-pmid 25755648?><pub-id pub-id-type="pmid">25755648</pub-id></element-citation></ref><ref id="CR119"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montalban</surname><given-names>X</given-names></name><name><surname>Comi</surname><given-names>G</given-names></name><name><surname>O&#x02019;Connor</surname><given-names>P</given-names></name><name><surname>Gold</surname><given-names>S</given-names></name><name><surname>de Vera</surname><given-names>A</given-names></name><name><surname>Eckert</surname><given-names>B</given-names></name><etal/></person-group><article-title>Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health-related quality of life in a phase II study</article-title><source>Mult Scler</source><year>2011</year><volume>17</volume><issue>11</issue><fpage>1341</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1177/1352458511411061</pub-id><?supplied-pmid 21727148?><pub-id pub-id-type="pmid">21727148</pub-id></element-citation></ref><ref id="CR120"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calkwood</surname><given-names>J</given-names></name><name><surname>Cree</surname><given-names>B</given-names></name><name><surname>Crayton</surname><given-names>H</given-names></name><name><surname>Kantor</surname><given-names>D</given-names></name><name><surname>Steingo</surname><given-names>B</given-names></name><name><surname>Barbato</surname><given-names>L</given-names></name><etal/></person-group><article-title>Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial</article-title><source>BMC Neurol</source><year>2014</year><volume>14</volume><issue>1</issue><fpage>220</fpage><pub-id pub-id-type="doi">10.1186/s12883-014-0220-1</pub-id><?supplied-pmid 25424122?><pub-id pub-id-type="pmid">25424122</pub-id></element-citation></ref><ref id="CR121"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riera</surname><given-names>R</given-names></name><name><surname>Porf&#x000ed;rio</surname><given-names>GJ</given-names></name><name><surname>Torloni</surname><given-names>MR</given-names></name></person-group><article-title>Alemtuzumab for multiple sclerosis</article-title><source>Cochrane Database Syst Rev</source><year>2016</year><volume>4</volume><fpage>CD011203</fpage><?supplied-pmid 27082500?><pub-id pub-id-type="pmid">27082500</pub-id></element-citation></ref><ref id="CR122"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kappos</surname><given-names>L</given-names></name><name><surname>Gold</surname><given-names>R</given-names></name><name><surname>Miller</surname><given-names>DH</given-names></name><name><surname>MacManus</surname><given-names>DG</given-names></name><name><surname>Havrdova</surname><given-names>E</given-names></name><name><surname>Limmroth</surname><given-names>V</given-names></name><etal/></person-group><article-title>Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study</article-title><source>Lancet</source><year>2008</year><volume>372</volume><issue>9648</issue><fpage>1463</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(08)61619-0</pub-id><?supplied-pmid 18970976?><pub-id pub-id-type="pmid">18970976</pub-id></element-citation></ref><ref id="CR123"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Connor</surname><given-names>P</given-names></name><name><surname>Wolinsky</surname><given-names>JS</given-names></name><name><surname>Confavreux</surname><given-names>C</given-names></name><name><surname>Comi</surname><given-names>G</given-names></name><name><surname>Kappos</surname><given-names>L</given-names></name><name><surname>Olsson</surname><given-names>TP</given-names></name><etal/></person-group><article-title>Randomized trial of oral teriflunomide for relapsing multiple sclerosis</article-title><source>N Engl J Med</source><year>2011</year><volume>365</volume><issue>14</issue><fpage>1293</fpage><lpage>303</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1014656</pub-id><?supplied-pmid 21991951?><pub-id pub-id-type="pmid">21991951</pub-id></element-citation></ref><ref id="CR124"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lerdal</surname><given-names>A</given-names></name><name><surname>Bakken</surname><given-names>LN</given-names></name><name><surname>Kouwenhoven</surname><given-names>SE</given-names></name><name><surname>Pedersen</surname><given-names>G</given-names></name><name><surname>Kirkevold</surname><given-names>M</given-names></name><name><surname>Finset</surname><given-names>A</given-names></name><etal/></person-group><article-title>Poststroke fatigue&#x02014;a review</article-title><source>J Pain Symptom Manage</source><year>2009</year><volume>38</volume><issue>6</issue><fpage>928</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1016/j.jpainsymman.2009.04.028</pub-id><?supplied-pmid 19811888?><pub-id pub-id-type="pmid">19811888</pub-id></element-citation></ref><ref id="CR125"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedman</surname><given-names>JH</given-names></name><name><surname>Brown</surname><given-names>RG</given-names></name><name><surname>Comella</surname><given-names>C</given-names></name><name><surname>Garber</surname><given-names>CE</given-names></name><name><surname>Krupp</surname><given-names>LB</given-names></name><name><surname>Lou</surname><given-names>J-S</given-names></name><etal/></person-group><article-title>Fatigue in Parkinson&#x02019;s disease: a review</article-title><source>Mov Disord</source><year>2007</year><volume>22</volume><issue>3</issue><fpage>297</fpage><lpage>308</lpage><pub-id pub-id-type="doi">10.1002/mds.21240</pub-id><?supplied-pmid 17133511?><pub-id pub-id-type="pmid">17133511</pub-id></element-citation></ref><ref id="CR126"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thames</surname><given-names>AD</given-names></name><name><surname>Castellon</surname><given-names>SA</given-names></name><name><surname>Singer</surname><given-names>EJ</given-names></name><name><surname>Nagarajan</surname><given-names>R</given-names></name><name><surname>Sarma</surname><given-names>MK</given-names></name><name><surname>Smith</surname><given-names>J</given-names></name><etal/></person-group><article-title>Neuroimaging abnormalities, neurocognitive function, and fatigue in patients with hepatitis C</article-title><source>Neurol Neuroimmunol Neuroinflamm</source><year>2015</year><volume>2</volume><issue>1</issue><fpage>e59</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1212/NXI.0000000000000059</pub-id><?supplied-pmid 25610883?><pub-id pub-id-type="pmid">25610883</pub-id></element-citation></ref><ref id="CR127"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Achiron</surname><given-names>A</given-names></name><name><surname>Givon</surname><given-names>U</given-names></name><name><surname>Magalashvili</surname><given-names>D</given-names></name><name><surname>Dolev</surname><given-names>M</given-names></name><name><surname>Liraz Zaltzman</surname><given-names>S</given-names></name><name><surname>Kalron</surname><given-names>A</given-names></name><etal/></person-group><article-title>Effect of alfacalcidol on multiple sclerosis-related fatigue: a randomized, double-blind placebo-controlled study</article-title><source>Mult Scler</source><year>2015</year><volume>21</volume><issue>6</issue><fpage>767</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1177/1352458514554053</pub-id><?supplied-pmid 25344375?><pub-id pub-id-type="pmid">25344375</pub-id></element-citation></ref><ref id="CR128"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moller</surname><given-names>F</given-names></name><name><surname>Poettgen</surname><given-names>J</given-names></name><name><surname>Broemel</surname><given-names>F</given-names></name><name><surname>Neuhaus</surname><given-names>A</given-names></name><name><surname>Daumer</surname><given-names>M</given-names></name><name><surname>Heesen</surname><given-names>C</given-names></name></person-group><article-title>HAGIL (Hamburg Vigil Study): a randomized placebo-controlled double-blind study with modafinil for treatment of fatigue in patients with multiple sclerosis</article-title><source>Mult Scler</source><year>2011</year><volume>17</volume><issue>8</issue><fpage>1002</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1177/1352458511402410</pub-id><?supplied-pmid 21561959?><pub-id pub-id-type="pmid">21561959</pub-id></element-citation></ref><ref id="CR129"><label>129.</label><mixed-citation publication-type="other">Branas P. Treatments for fatigue in multiple sclerosis: a rapid and systematic review. Health Technol Assess. 2000;4(27):1-61. <ext-link ext-link-type="uri" xlink:href="http://www.journalslibrary.nihr.ac.uk/hta/volume-4/issue-27">http://www.journalslibrary.nihr.ac.uk/hta/volume-4/issue-27</ext-link>.</mixed-citation></ref><ref id="CR130"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shaygannejad</surname><given-names>V</given-names></name><name><surname>Janghorbani</surname><given-names>M</given-names></name><name><surname>Ashtari</surname><given-names>F</given-names></name><name><surname>Zakeri</surname><given-names>H</given-names></name></person-group><article-title>Comparison of the effect of aspirin and amantadine for the treatment of fatigue in multiple sclerosis: a randomized, blinded, crossover study</article-title><source>Neurol Res</source><year>2012</year><volume>34</volume><issue>9</issue><fpage>854</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1179/1743132812Y.0000000081</pub-id><?supplied-pmid 22979982?><pub-id pub-id-type="pmid">22979982</pub-id></element-citation></ref><ref id="CR131"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ashtari</surname><given-names>F</given-names></name><name><surname>Fatehi</surname><given-names>F</given-names></name><name><surname>Shaygannejad</surname><given-names>V</given-names></name><name><surname>Chitsaz</surname><given-names>A</given-names></name></person-group><article-title>Does amantadine have favourable effects on fatigue in Persian patients suffering from multiple sclerosis?</article-title><source>Neurol Neurochir Pol</source><year>2009</year><volume>43</volume><issue>5</issue><fpage>428</fpage><lpage>32</lpage><?supplied-pmid 20054744?><pub-id pub-id-type="pmid">20054744</pub-id></element-citation></ref><ref id="CR132"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossini</surname><given-names>PM</given-names></name><name><surname>Pasqualetti</surname><given-names>P</given-names></name><name><surname>Pozzilli</surname><given-names>C</given-names></name><name><surname>Grasso</surname><given-names>MG</given-names></name><name><surname>Millefiorini</surname><given-names>E</given-names></name><name><surname>Graceffa</surname><given-names>A</given-names></name><etal/></person-group><article-title>Fatigue in progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine</article-title><source>Mult Scler</source><year>2001</year><volume>7</volume><issue>6</issue><fpage>354</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1191/135245801701567050</pub-id><?supplied-pmid 11795455?><pub-id pub-id-type="pmid">11795455</pub-id></element-citation></ref><ref id="CR133"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weinshenker</surname><given-names>BG</given-names></name><name><surname>Penman</surname><given-names>M</given-names></name><name><surname>Bass</surname><given-names>B</given-names></name><name><surname>Ebers</surname><given-names>GC</given-names></name><name><surname>Rice</surname><given-names>GP</given-names></name></person-group><article-title>A double-blind, randomized, crossover trial of pemoline in fatigue associated with multiple sclerosis</article-title><source>Neurology</source><year>1992</year><volume>42</volume><issue>8</issue><fpage>1468</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1212/WNL.42.8.1468</pub-id><?supplied-pmid 1641137?><pub-id pub-id-type="pmid">1641137</pub-id></element-citation></ref><ref id="CR134"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>RA</given-names></name><name><surname>Fisher</surname><given-names>M</given-names></name></person-group><article-title>Amantadine treatment of fatigue associated with multiple sclerosis</article-title><source>Arch Neurol</source><year>1989</year><volume>46</volume><issue>6</issue><fpage>676</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1001/archneur.1989.00520420096030</pub-id><?supplied-pmid 2730380?><pub-id pub-id-type="pmid">2730380</pub-id></element-citation></ref><ref id="CR135"><label>135.</label><mixed-citation publication-type="other">A randomized controlled trial of amantadine in fatigue associated with multiple sclerosis. The Canadian MS Research Group. Can J Neurol Sci. 1987;14(3):273&#x02013;8.</mixed-citation></ref><ref id="CR136"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asano</surname><given-names>M</given-names></name><name><surname>Finlayson</surname><given-names>ML</given-names></name></person-group><article-title>Meta-analysis of three different types of fatigue management interventions for people with multiple sclerosis: exercise, education, and medication</article-title><source>Mult Scler Int</source><year>2014</year><volume>2014</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1155/2014/798285</pub-id></element-citation></ref><ref id="CR137"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lange</surname><given-names>R</given-names></name><name><surname>Volkmer</surname><given-names>M</given-names></name><name><surname>Heesen</surname><given-names>C</given-names></name><name><surname>Liepert</surname><given-names>J</given-names></name></person-group><article-title>Modafinil effects in multiple sclerosis patients with fatigue</article-title><source>J Neurol</source><year>2009</year><volume>256</volume><issue>4</issue><fpage>645</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1007/s00415-009-0152-7</pub-id><?supplied-pmid 19367356?><pub-id pub-id-type="pmid">19367356</pub-id></element-citation></ref><ref id="CR138"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krupp</surname><given-names>LB</given-names></name><name><surname>Coyle</surname><given-names>PK</given-names></name><name><surname>Doscher</surname><given-names>C</given-names></name><name><surname>Miller</surname><given-names>A</given-names></name><name><surname>Cross</surname><given-names>AH</given-names></name><name><surname>Jandorf</surname><given-names>L</given-names></name><etal/></person-group><article-title>Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo</article-title><source>Neurology</source><year>1995</year><volume>45</volume><issue>11</issue><fpage>1956</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1212/WNL.45.11.1956</pub-id><?supplied-pmid 7501140?><pub-id pub-id-type="pmid">7501140</pub-id></element-citation></ref><ref id="CR139"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenberg</surname><given-names>GA</given-names></name><name><surname>Appenzeller</surname><given-names>O</given-names></name></person-group><article-title>Amantadine, fatigue, and multiple sclerosis</article-title><source>Arch Neurol</source><year>1988</year><volume>45</volume><issue>10</issue><fpage>1104</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1001/archneur.1988.00520340058012</pub-id><?supplied-pmid 2972270?><pub-id pub-id-type="pmid">2972270</pub-id></element-citation></ref><ref id="CR140"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomassini</surname><given-names>V</given-names></name><name><surname>Pozzilli</surname><given-names>C</given-names></name><name><surname>Onesti</surname><given-names>E</given-names></name><name><surname>Pasqualetti</surname><given-names>P</given-names></name><name><surname>Marinelli</surname><given-names>F</given-names></name><name><surname>Pisani</surname><given-names>A</given-names></name><etal/></person-group><article-title>Comparison of the effects of acetyl l-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial</article-title><source>J Neurol Sci</source><year>2004</year><volume>218</volume><issue>1&#x02013;2</issue><fpage>103</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.jns.2003.11.005</pub-id><?supplied-pmid 14759641?><pub-id pub-id-type="pmid">14759641</pub-id></element-citation></ref><ref id="CR141"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peuckmann-Post</surname><given-names>V</given-names></name><name><surname>Elsner</surname><given-names>F</given-names></name><name><surname>Krumm</surname><given-names>N</given-names></name><name><surname>Trottenberg</surname><given-names>P</given-names></name><name><surname>Radbruch</surname><given-names>L</given-names></name></person-group><article-title>Pharmacological treatments for fatigue associated with palliative care</article-title><source>Cochrane Database Syst Rev.</source><year>2010</year><volume>11</volume><fpage>CD006788</fpage></element-citation></ref><ref id="CR142"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>M&#x000fc;cke</surname><given-names>M</given-names></name></person-group><article-title>Mochamat, Cuhls H, Peuckmann-Post V, Minton O, Stone P, et al</article-title><source>Pharmacological treatments for fatigue associated with palliative care. Cochrane Database Syst Rev.</source><year>2015</year><volume>5</volume><fpage>CD006788</fpage></element-citation></ref><ref id="CR143"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pucci</surname><given-names>E</given-names></name><name><surname>Bran&#x000e3;s</surname><given-names>P</given-names></name><name><surname>D&#x02019;Amico</surname><given-names>R</given-names></name><name><surname>Giuliani</surname><given-names>G</given-names></name><name><surname>Solari</surname><given-names>A</given-names></name><name><surname>Taus</surname><given-names>C</given-names></name></person-group><article-title>Amantadine for fatigue in multiple sclerosis</article-title><source>Cochrane Database Syst Rev</source><year>2007</year><volume>1</volume><fpage>CD002818</fpage></element-citation></ref><ref id="CR144"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tejani</surname><given-names>AM</given-names></name><name><surname>Wasdell</surname><given-names>M</given-names></name><name><surname>Spiwak</surname><given-names>R</given-names></name><name><surname>Rowell</surname><given-names>G</given-names></name><name><surname>Nathwani</surname><given-names>S</given-names></name></person-group><article-title>Carnitine for fatigue in multiple sclerosis</article-title><source>Cochrane Database Syst Rev.</source><year>2010</year><volume>2</volume><fpage>CD007280</fpage></element-citation></ref><ref id="CR145"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wingerchuk</surname><given-names>DM</given-names></name><name><surname>Benarroch</surname><given-names>EE</given-names></name><name><surname>O&#x02019;Brien</surname><given-names>PC</given-names></name><name><surname>Keegan</surname><given-names>BM</given-names></name><name><surname>Lucchinetti</surname><given-names>CF</given-names></name><name><surname>Noseworthy</surname><given-names>JH</given-names></name><etal/></person-group><article-title>A randomized controlled crossover trial of aspirin for fatigue in multiple sclerosis</article-title><source>Neurology</source><year>2005</year><volume>64</volume><issue>7</issue><fpage>1267</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1212/01.WNL.0000156803.23698.9A</pub-id><?supplied-pmid 15824361?><pub-id pub-id-type="pmid">15824361</pub-id></element-citation></ref><ref id="CR146"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Macdonell</surname><given-names>R</given-names></name><name><surname>Nagels</surname><given-names>G</given-names></name><name><surname>Laplaud</surname><given-names>D-A</given-names></name><name><surname>Pozzilli</surname><given-names>C</given-names></name><name><surname>de Jong</surname><given-names>B</given-names></name></person-group><article-title>Martins da Silva A, et al. Improved patient-reported health impact of multiple sclerosis: The ENABLE study of PR-fampridine</article-title><source>Mult Scler</source><year>2016</year><volume>22</volume><issue>7</issue><fpage>944</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1177/1352458515606809</pub-id><?supplied-pmid 26447066?><pub-id pub-id-type="pmid">26447066</pub-id></element-citation></ref><ref id="CR147"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Applebee</surname><given-names>A</given-names></name><name><surname>Goodman</surname><given-names>AD</given-names></name><name><surname>Mayadev</surname><given-names>AS</given-names></name><name><surname>Bethoux</surname><given-names>F</given-names></name><name><surname>Goldman</surname><given-names>MD</given-names></name><name><surname>Klingler</surname><given-names>M</given-names></name><etal/></person-group><article-title>Effects of dalfampridine extended-release tablets on 6-minute walk distance in patients with multiple sclerosis: a post hoc analysis of a double-blind, placebo-controlled trial</article-title><source>Clin Ther</source><year>2015</year><volume>37</volume><issue>12</issue><fpage>2780</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.clinthera.2015.10.014</pub-id><?supplied-pmid 26565077?><pub-id pub-id-type="pmid">26565077</pub-id></element-citation></ref><ref id="CR148"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allart</surname><given-names>E</given-names></name><name><surname>Benoit</surname><given-names>A</given-names></name><name><surname>Blanchard-Dauphin</surname><given-names>A</given-names></name><name><surname>Tiffreau</surname><given-names>V</given-names></name><name><surname>Thevenon</surname><given-names>A</given-names></name><name><surname>Zephir</surname><given-names>H</given-names></name><etal/></person-group><article-title>Sustained-released fampridine in multiple sclerosis: effects on gait parameters, arm function, fatigue, and quality of life</article-title><source>J Neurol</source><year>2015</year><volume>262</volume><issue>8</issue><fpage>1936</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1007/s00415-015-7797-1</pub-id><?supplied-pmid 26041616?><pub-id pub-id-type="pmid">26041616</pub-id></element-citation></ref><ref id="CR149"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pavsic</surname><given-names>K</given-names></name><name><surname>Pelicon</surname><given-names>K</given-names></name><name><surname>Ledinek</surname><given-names>AH</given-names></name><name><surname>Sega</surname><given-names>S</given-names></name></person-group><article-title>Short-term impact of fampridine on motor and cognitive functions, mood and quality of life among multiple sclerosis patients</article-title><source>Clin Neurol Neurosurg</source><year>2015</year><volume>139</volume><fpage>35</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1016/j.clineuro.2015.08.023</pub-id><?supplied-pmid 26363365?><pub-id pub-id-type="pmid">26363365</pub-id></element-citation></ref><ref id="CR150"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grossman</surname><given-names>P</given-names></name><name><surname>Kappos</surname><given-names>L</given-names></name><name><surname>Gensicke</surname><given-names>H</given-names></name><name><surname>D&#x02019;Souza</surname><given-names>M</given-names></name><name><surname>Mohr</surname><given-names>DC</given-names></name><name><surname>Penner</surname><given-names>IK</given-names></name><etal/></person-group><article-title>MS quality of life, depression, and fatigue improve after mindfulness training: a randomized trial</article-title><source>Neurology</source><year>2010</year><volume>75</volume><issue>13</issue><fpage>1141</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e3181f4d80d</pub-id><?supplied-pmid 20876468?><pub-id pub-id-type="pmid">20876468</pub-id></element-citation></ref><ref id="CR151"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hebert</surname><given-names>JR</given-names></name><name><surname>Corboy</surname><given-names>JR</given-names></name><name><surname>Manago</surname><given-names>MM</given-names></name><name><surname>Schenkman</surname><given-names>M</given-names></name></person-group><article-title>Effects of vestibular rehabilitation on multiple sclerosis-related fatigue and upright postural control: a randomized controlled trial</article-title><source>Phys Ther</source><year>2011</year><volume>91</volume><issue>8</issue><fpage>1166</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.2522/ptj.20100399</pub-id><?supplied-pmid 21680771?><pub-id pub-id-type="pmid">21680771</pub-id></element-citation></ref><ref id="CR152"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rietberg</surname><given-names>MB</given-names></name><name><surname>Brooks</surname><given-names>D</given-names></name><name><surname>Uitdehaag</surname><given-names>BM</given-names></name><name><surname>Kwakkel</surname><given-names>G</given-names></name></person-group><article-title>Exercise therapy for multiple sclerosis</article-title><source>Cochrane Database Syst Rev.</source><year>2005</year><volume>1</volume><fpage>CD003980</fpage></element-citation></ref><ref id="CR153"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D&#x000f6;ring</surname><given-names>A</given-names></name><name><surname>Pfueller</surname><given-names>CF</given-names></name><name><surname>Paul</surname><given-names>F</given-names></name><name><surname>D&#x000f6;rr</surname><given-names>J</given-names></name></person-group><article-title>Exercise in multiple sclerosis&#x02014;an integral component of disease management</article-title><source>EPMA J</source><year>2011</year><volume>3</volume><issue>1</issue><fpage>2</fpage><pub-id pub-id-type="doi">10.1007/s13167-011-0136-4</pub-id><?supplied-pmid 22738091?><pub-id pub-id-type="pmid">22738091</pub-id></element-citation></ref><ref id="CR154"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moss-Morris</surname><given-names>R</given-names></name><name><surname>McCrone</surname><given-names>P</given-names></name><name><surname>Yardley</surname><given-names>L</given-names></name><name><surname>van Kessel</surname><given-names>K</given-names></name><name><surname>Wills</surname><given-names>G</given-names></name><name><surname>Dennison</surname><given-names>L</given-names></name></person-group><article-title>A pilot randomised controlled trial of an Internet-based cognitive behavioural therapy self-management programme (MS Invigor8) for multiple sclerosis fatigue</article-title><source>Behav Res Ther</source><year>2012</year><volume>50</volume><issue>6</issue><fpage>415</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/j.brat.2012.03.001</pub-id><?supplied-pmid 22516321?><pub-id pub-id-type="pmid">22516321</pub-id></element-citation></ref><ref id="CR155"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Kessel</surname><given-names>K</given-names></name><name><surname>Moss-Morris</surname><given-names>R</given-names></name><name><surname>Willoughby</surname><given-names>E</given-names></name><name><surname>Chalder</surname><given-names>T</given-names></name><name><surname>Johnson</surname><given-names>MH</given-names></name><name><surname>Robinson</surname><given-names>E</given-names></name></person-group><article-title>A randomized controlled trial of cognitive behavior therapy for multiple sclerosis fatigue</article-title><source>Psychosom Med</source><year>2008</year><volume>70</volume><issue>2</issue><fpage>205</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1097/PSY.0b013e3181643065</pub-id><?supplied-pmid 18256342?><pub-id pub-id-type="pmid">18256342</pub-id></element-citation></ref><ref id="CR156"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohr</surname><given-names>DC</given-names></name><name><surname>Hart</surname><given-names>SL</given-names></name><name><surname>Goldberg</surname><given-names>A</given-names></name></person-group><article-title>Effects of treatment for depression on fatigue in multiple sclerosis</article-title><source>Psychosom Med</source><year>2003</year><volume>65</volume><issue>4</issue><fpage>542</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1097/01.PSY.0000074757.11682.96</pub-id><?supplied-pmid 12883103?><pub-id pub-id-type="pmid">12883103</pub-id></element-citation></ref><ref id="CR157"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>PW</given-names></name><name><surname>Thomas</surname><given-names>S</given-names></name><name><surname>Kersten</surname><given-names>P</given-names></name><name><surname>Jones</surname><given-names>R</given-names></name><name><surname>Slingsby</surname><given-names>V</given-names></name><name><surname>Nock</surname><given-names>A</given-names></name><etal/></person-group><article-title>One year follow-up of a pragmatic multi-centre randomised controlled trial of a group-based fatigue management programme (FACETS) for people with multiple sclerosis</article-title><source>BMC Neurol</source><year>2014</year><volume>14</volume><issue>1</issue><fpage>109</fpage><pub-id pub-id-type="doi">10.1186/1471-2377-14-109</pub-id><?supplied-pmid 24886398?><pub-id pub-id-type="pmid">24886398</pub-id></element-citation></ref><ref id="CR158"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veauthier</surname><given-names>C</given-names></name><name><surname>Gaede</surname><given-names>G</given-names></name><name><surname>Radbruch</surname><given-names>H</given-names></name><name><surname>Wernecke</surname><given-names>K-D</given-names></name><name><surname>Paul</surname><given-names>F</given-names></name></person-group><article-title>Sleep disorders reduce health-related quality of life in multiple sclerosis (Nottingham Health Profile Data in Patients with Multiple Sclerosis)</article-title><source>Int J Mol Sci</source><year>2015</year><volume>16</volume><issue>7</issue><fpage>16514</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.3390/ijms160716514</pub-id><?supplied-pmid 26197315?><pub-id pub-id-type="pmid">26197315</pub-id></element-citation></ref><ref id="CR159"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berrigan</surname><given-names>LI</given-names></name><name><surname>Fisk</surname><given-names>JD</given-names></name><name><surname>Patten</surname><given-names>SB</given-names></name><name><surname>Tremlett</surname><given-names>H</given-names></name><name><surname>Wolfson</surname><given-names>C</given-names></name><name><surname>Warren</surname><given-names>S</given-names></name><etal/></person-group><article-title>Health-related quality of life in multiple sclerosis: direct and indirect effects of comorbidity</article-title><source>Neurology</source><year>2016</year><volume>86</volume><issue>15</issue><fpage>1417</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000002564</pub-id></element-citation></ref><ref id="CR160"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanigawa</surname><given-names>T</given-names></name></person-group><article-title>Obstructive sleep apnea: its prevention and screening may contribute to the prevention of hypertension, diabetes and cardiovascular diseases</article-title><source>EPMA J</source><year>2011</year><volume>2</volume><issue>1</issue><fpage>83</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1007/s13167-011-0073-2</pub-id><?supplied-pmid 23199130?><pub-id pub-id-type="pmid">23199130</pub-id></element-citation></ref><ref id="CR161"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tuleta</surname><given-names>I</given-names></name><name><surname>Pabst</surname><given-names>S</given-names></name><name><surname>Juergens</surname><given-names>UR</given-names></name><name><surname>Nickenig</surname><given-names>G</given-names></name><name><surname>Skowasch</surname><given-names>D</given-names></name></person-group><article-title>Obstructive sleep apnoea as a risk factor for atherosclerosis&#x02014;implication for preventive and personalised treatment</article-title><source>EPMA J</source><year>2011</year><volume>2</volume><issue>1</issue><fpage>39</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1007/s13167-011-0070-5</pub-id><?supplied-pmid 23199125?><pub-id pub-id-type="pmid">23199125</pub-id></element-citation></ref><ref id="CR162"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olson</surname><given-names>L</given-names></name><name><surname>Cole</surname><given-names>M</given-names></name><name><surname>Ambrogetti</surname><given-names>A</given-names></name></person-group><article-title>Correlations among Epworth Sleepiness Scale scores, multiple sleep latency tests and psychological symptoms</article-title><source>J Sleep Res</source><year>1998</year><volume>7</volume><issue>4</issue><fpage>248</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2869.1998.00123.x</pub-id><?supplied-pmid 9844851?><pub-id pub-id-type="pmid">9844851</pub-id></element-citation></ref><ref id="CR163"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bastien</surname><given-names>C</given-names></name></person-group><article-title>Validation of the Insomnia Severity Index as an outcome measure for insomnia research</article-title><source>Sleep Med</source><year>2001</year><volume>2</volume><issue>4</issue><fpage>297</fpage><lpage>307</lpage><pub-id pub-id-type="doi">10.1016/S1389-9457(00)00065-4</pub-id><?supplied-pmid 11438246?><pub-id pub-id-type="pmid">11438246</pub-id></element-citation></ref><ref id="CR164"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walters</surname><given-names>AS</given-names></name><name><surname>Frauscher</surname><given-names>B</given-names></name><name><surname>Allen</surname><given-names>R</given-names></name><name><surname>Benes</surname><given-names>H</given-names></name><name><surname>Chaudhuri</surname><given-names>KR</given-names></name><name><surname>Garcia-Borreguero</surname><given-names>D</given-names></name><etal/></person-group><article-title>Review of diagnostic instruments for the restless legs syndrome/Willis-Ekbom Disease (RLS/WED): critique and recommendations</article-title><source>J Clin Sleep Med</source><year>2014</year><volume>10</volume><issue>12</issue><fpage>1343</fpage><lpage>9</lpage><?supplied-pmid 25348242?><pub-id pub-id-type="pmid">25348242</pub-id></element-citation></ref><ref id="CR165"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flachenecker</surname><given-names>P</given-names></name><name><surname>Meissner</surname><given-names>H</given-names></name></person-group><article-title>Fatigue in multiple sclerosis presenting as acute relapse: subjective and objective assessment</article-title><source>Mult Scler</source><year>2008</year><volume>14</volume><issue>2</issue><fpage>274</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1177/1352458507082480</pub-id><?supplied-pmid 18337428?><pub-id pub-id-type="pmid">18337428</pub-id></element-citation></ref><ref id="CR166"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allen</surname><given-names>RP</given-names></name><name><surname>Picchietti</surname><given-names>DL</given-names></name><name><surname>Garcia-Borreguero</surname><given-names>D</given-names></name><name><surname>Ondo</surname><given-names>WG</given-names></name><name><surname>Walters</surname><given-names>AS</given-names></name><name><surname>Winkelman</surname><given-names>JW</given-names></name><etal/></person-group><article-title>Restless legs syndrome/Willis&#x02013;Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria&#x02014;history, rationale, description, and significance</article-title><source>Sleep Med</source><year>2014</year><volume>15</volume><issue>8</issue><fpage>860</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1016/j.sleep.2014.03.025</pub-id><?supplied-pmid 25023924?><pub-id pub-id-type="pmid">25023924</pub-id></element-citation></ref><ref id="CR167"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Yin</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Liang</surname><given-names>W</given-names></name><name><surname>Wei</surname><given-names>Q</given-names></name></person-group><article-title>Efficacy of physical activity counseling plus sleep restriction therapy on the patients with chronic insomnia</article-title><source>Neuropsychiatr Dis Treat</source><year>2015</year><volume>11</volume><fpage>2771</fpage><pub-id pub-id-type="doi">10.2147/NDT.S94724</pub-id><?supplied-pmid 26566369?><pub-id pub-id-type="pmid">26566369</pub-id></element-citation></ref><ref id="CR168"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>CS</given-names></name><name><surname>Lee</surname><given-names>SD</given-names></name><name><surname>Kang</surname><given-names>S-H</given-names></name><name><surname>Park</surname><given-names>HY</given-names></name><name><surname>Yoon</surname><given-names>I-Y</given-names></name></person-group><article-title>Comparison of the efficacies of oral iron and pramipexole for the treatment of restless legs syndrome patients with low serum ferritin</article-title><source>Eur J Neurol</source><year>2014</year><volume>21</volume><issue>2</issue><fpage>260</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1111/ene.12286</pub-id><?supplied-pmid 24267148?><pub-id pub-id-type="pmid">24267148</pub-id></element-citation></ref><ref id="CR169"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buchfuhrer</surname><given-names>MJ</given-names></name></person-group><article-title>Strategies for the treatment of restless legs syndrome</article-title><source>Neurotherapeutics</source><year>2012</year><volume>9</volume><issue>4</issue><fpage>776</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1007/s13311-012-0139-4</pub-id><?supplied-pmid 22923001?><pub-id pub-id-type="pmid">22923001</pub-id></element-citation></ref><ref id="CR170"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allen</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Soaita</surname><given-names>A</given-names></name><name><surname>Wohlberg</surname><given-names>C</given-names></name><name><surname>Knapp</surname><given-names>L</given-names></name><name><surname>Peterson</surname><given-names>BT</given-names></name><etal/></person-group><article-title>A randomized, double-blind, 6-week, dose-ranging study of pregabalin in patients with restless legs syndrome</article-title><source>Sleep Med</source><year>2010</year><volume>11</volume><issue>6</issue><fpage>512</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.sleep.2010.03.003</pub-id><?supplied-pmid 20466589?><pub-id pub-id-type="pmid">20466589</pub-id></element-citation></ref><ref id="CR171"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abetz</surname><given-names>L</given-names></name><name><surname>Arbuckle</surname><given-names>R</given-names></name><name><surname>Allen</surname><given-names>RP</given-names></name><name><surname>Garcia-Borreguero</surname><given-names>D</given-names></name><name><surname>Hening</surname><given-names>W</given-names></name><name><surname>Walters</surname><given-names>AS</given-names></name><etal/></person-group><article-title>The reliability, validity and responsiveness of the International Restless Legs Syndrome Study Group rating scale and subscales in a clinical-trial setting</article-title><source>Sleep Med</source><year>2006</year><volume>7</volume><issue>4</issue><fpage>340</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.sleep.2005.12.011</pub-id><?supplied-pmid 16713344?><pub-id pub-id-type="pmid">16713344</pub-id></element-citation></ref><ref id="CR172"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kyle</surname><given-names>SD</given-names></name><name><surname>Aquino</surname><given-names>MRJ</given-names></name><name><surname>Miller</surname><given-names>CB</given-names></name><name><surname>Henry</surname><given-names>AL</given-names></name><name><surname>Crawford</surname><given-names>MR</given-names></name><name><surname>Espie</surname><given-names>CA</given-names></name><etal/></person-group><article-title>Towards standardisation and improved understanding of sleep restriction therapy for insomnia disorder: a systematic examination of CBT-I trial content</article-title><source>Sleep Med Rev</source><year>2015</year><volume>23</volume><fpage>83</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.smrv.2015.02.003</pub-id><?supplied-pmid 25771293?><pub-id pub-id-type="pmid">25771293</pub-id></element-citation></ref><ref id="CR173"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>DJ</given-names></name><name><surname>Schmidt-Nowara</surname><given-names>W</given-names></name><name><surname>Jessop</surname><given-names>CA</given-names></name><name><surname>Ahearn</surname><given-names>J</given-names></name></person-group><article-title>Sleep restriction therapy and hypnotic withdrawal versus sleep hygiene education in hypnotic using patients with insomnia</article-title><source>J Clin Sleep Med</source><year>2010</year><volume>6</volume><issue>2</issue><fpage>169</fpage><lpage>75</lpage><?supplied-pmid 20411695?><pub-id pub-id-type="pmid">20411695</pub-id></element-citation></ref><ref id="CR174"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>CB</given-names></name><name><surname>Espie</surname><given-names>CA</given-names></name><name><surname>Epstein</surname><given-names>DR</given-names></name><name><surname>Friedman</surname><given-names>L</given-names></name><name><surname>Morin</surname><given-names>CM</given-names></name><name><surname>Pigeon</surname><given-names>WR</given-names></name><etal/></person-group><article-title>The evidence base of sleep restriction therapy for treating insomnia disorder</article-title><source>Sleep Med Rev</source><year>2014</year><volume>18</volume><issue>5</issue><fpage>415</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1016/j.smrv.2014.01.006</pub-id><?supplied-pmid 24629826?><pub-id pub-id-type="pmid">24629826</pub-id></element-citation></ref><ref id="CR175"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morin</surname><given-names>AK</given-names></name><name><surname>Jarvis</surname><given-names>CI</given-names></name><name><surname>Lynch</surname><given-names>AM</given-names></name></person-group><article-title>Therapeutic options for sleep-maintenance and sleep-onset insomnia</article-title><source>Pharmacotherapy</source><year>2007</year><volume>27</volume><issue>1</issue><fpage>89</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1592/phco.27.1.89</pub-id><?supplied-pmid 17192164?><pub-id pub-id-type="pmid">17192164</pub-id></element-citation></ref><ref id="CR176"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ancoli-Israel</surname><given-names>S</given-names></name><name><surname>Bliwise</surname><given-names>DL</given-names></name><name><surname>N&#x000f8;rgaard</surname><given-names>JP</given-names></name></person-group><article-title>The effect of nocturia on sleep</article-title><source>Sleep Med Rev</source><year>2011</year><volume>15</volume><issue>2</issue><fpage>91</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.smrv.2010.03.002</pub-id><?supplied-pmid 20965130?><pub-id pub-id-type="pmid">20965130</pub-id></element-citation></ref><ref id="CR177"><label>177.</label><mixed-citation publication-type="other">Depressive disorders. In: Diagnostic and Statistical Manual of Mental Disorders. Fifth Edition. American Psychiatric Association; 2013 [cited 2016 May 19]. Available from:<ext-link ext-link-type="uri" xlink:href="http://psychiatryonline.org/doi/abs/10.1176/appi.books.9780890425596.dsm04">http://psychiatryonline.org/doi/abs/10.1176/appi.books.9780890425596.dsm04</ext-link>.</mixed-citation></ref><ref id="CR178"><label>178.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><source>International Statistical Classification of Diseases and Related Health Problems (ICD)</source><year>1994</year><edition>10</edition><publisher-loc>Geneva</publisher-loc><publisher-name>World Health Organization</publisher-name></element-citation></ref><ref id="CR179"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beck</surname><given-names>AT</given-names></name><name><surname>Steer</surname><given-names>RA</given-names></name></person-group><article-title>Internal consistencies of the original and revised Beck Depression Inventory</article-title><source>J Clin Psychol</source><year>1984</year><volume>40</volume><issue>6</issue><fpage>1365</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1002/1097-4679(198411)40:6&#x0003c;1365::AID-JCLP2270400615&#x0003e;3.0.CO;2-D</pub-id><?supplied-pmid 6511949?><pub-id pub-id-type="pmid">6511949</pub-id></element-citation></ref><ref id="CR180"><label>180.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patten</surname><given-names>SB</given-names></name><name><surname>Burton</surname><given-names>JM</given-names></name><name><surname>Fiest</surname><given-names>KM</given-names></name><name><surname>Wiebe</surname><given-names>S</given-names></name><name><surname>Bulloch</surname><given-names>AGM</given-names></name><name><surname>Koch</surname><given-names>M</given-names></name><etal/></person-group><article-title>Validity of four screening scales for major depression in MS</article-title><source>Mult Scler</source><year>2015</year><volume>21</volume><issue>8</issue><fpage>1064</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1177/1352458514559297</pub-id><?supplied-pmid 25583846?><pub-id pub-id-type="pmid">25583846</pub-id></element-citation></ref><ref id="CR181"><label>181.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minden</surname><given-names>SL</given-names></name><name><surname>Feinstein</surname><given-names>A</given-names></name><name><surname>Kalb</surname><given-names>RC</given-names></name><name><surname>Miller</surname><given-names>D</given-names></name><name><surname>Mohr</surname><given-names>DC</given-names></name><name><surname>Patten</surname><given-names>SB</given-names></name><etal/></person-group><article-title>Evidence-based guideline: assessment and management of psychiatric disorders in individuals with MS Report of the Guideline Development Subcommittee of the American Academy of Neurology</article-title><source>Neurology</source><year>2014</year><volume>82</volume><issue>2</issue><fpage>174</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000000013</pub-id><?supplied-pmid 24376275?><pub-id pub-id-type="pmid">24376275</pub-id></element-citation></ref><ref id="CR182"><label>182.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Golubnitschaja</surname><given-names>O</given-names></name><name><surname>Costigliola</surname><given-names>V</given-names></name><collab>EPMA</collab></person-group><article-title>General report &#x00026; recommendations in predictive, preventive and personalised medicine 2012: white paper of the European Association for Predictive, Preventive and Personalised Medicine</article-title><source>EPMA J</source><year>2012</year><volume>3</volume><issue>1</issue><fpage>14</fpage><pub-id pub-id-type="doi">10.1186/1878-5085-3-14</pub-id><?supplied-pmid 23116135?><pub-id pub-id-type="pmid">23116135</pub-id></element-citation></ref><ref id="CR183"><label>183.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>P&#x000e9;rez</surname><given-names>LP</given-names></name><name><surname>Gonz&#x000e1;lez</surname><given-names>RS</given-names></name><name><surname>L&#x000e1;zaro</surname><given-names>EB</given-names></name></person-group><article-title>Treatment of mood disorders in multiple Sclerosis</article-title><source>Curr Treat Options Neurol</source><year>2015</year><volume>17</volume><issue>1</issue><fpage>323</fpage><pub-id pub-id-type="doi">10.1007/s11940-014-0323-4</pub-id><?supplied-pmid 25398464?><pub-id pub-id-type="pmid">25398464</pub-id></element-citation></ref><ref id="CR184"><label>184.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koch</surname><given-names>MW</given-names></name><name><surname>Glazenborg</surname><given-names>A</given-names></name><name><surname>Uyttenboogaart</surname><given-names>M</given-names></name><name><surname>Mostert</surname><given-names>J</given-names></name><name><surname>De Keyser</surname><given-names>J</given-names></name></person-group><article-title>Pharmacologic treatment of depression in multiple sclerosis</article-title><source>Cochrane Database Syst Rev</source><year>2011</year><volume>2</volume><fpage>CD007295</fpage></element-citation></ref><ref id="CR185"><label>185.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fiest</surname><given-names>KM</given-names></name><name><surname>Walker</surname><given-names>JR</given-names></name><name><surname>Bernstein</surname><given-names>CN</given-names></name><name><surname>Graff</surname><given-names>LA</given-names></name><name><surname>Zarychanski</surname><given-names>R</given-names></name><name><surname>Abou-Setta</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Systematic review and meta-analysis of interventions for depression and anxiety in persons with multiple sclerosis</article-title><source>Mult Scler Relat Disord</source><year>2016</year><volume>5</volume><fpage>12</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1016/j.msard.2015.10.004</pub-id><?supplied-pmid 26856938?><pub-id pub-id-type="pmid">26856938</pub-id></element-citation></ref><ref id="CR186"><label>186.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paul</surname><given-names>F</given-names></name><name><surname>Veauthier</surname><given-names>C</given-names></name></person-group><article-title>Fatigue in multiple sclerosis: a diagnostic and therapeutic challenge</article-title><source>Expert Opin Pharmacother</source><year>2012</year><volume>13</volume><issue>6</issue><fpage>791</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1517/14656566.2012.667075</pub-id><?supplied-pmid 22424379?><pub-id pub-id-type="pmid">22424379</pub-id></element-citation></ref><ref id="CR187"><label>187.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bove</surname><given-names>R</given-names></name><name><surname>White</surname><given-names>CC</given-names></name><name><surname>Giovannoni</surname><given-names>G</given-names></name><name><surname>Glanz</surname><given-names>B</given-names></name><name><surname>Golubchikov</surname><given-names>V</given-names></name><name><surname>Hujol</surname><given-names>J</given-names></name><etal/></person-group><article-title>Evaluating more naturalistic outcome measures: a 1-year smartphone study in multiple sclerosis</article-title><source>Neurol Neuroimmunol Neuroinflamm</source><year>2015</year><volume>2</volume><issue>6</issue><fpage>e162</fpage><pub-id pub-id-type="doi">10.1212/NXI.0000000000000162</pub-id><?supplied-pmid 26516627?><pub-id pub-id-type="pmid">26516627</pub-id></element-citation></ref><ref id="CR188"><label>188.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mathiowetz</surname><given-names>VG</given-names></name><name><surname>Finlayson</surname><given-names>ML</given-names></name><name><surname>Matuska</surname><given-names>KM</given-names></name><name><surname>Chen</surname><given-names>HY</given-names></name><name><surname>Luo</surname><given-names>P</given-names></name></person-group><article-title>Randomized controlled trial of an energy conservation course for persons with multiple sclerosis</article-title><source>Mult Scler</source><year>2005</year><volume>11</volume><issue>5</issue><fpage>592</fpage><lpage>601</lpage><pub-id pub-id-type="doi">10.1191/1352458505ms1198oa</pub-id><?supplied-pmid 16193899?><pub-id pub-id-type="pmid">16193899</pub-id></element-citation></ref><ref id="CR189"><label>189.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kos</surname><given-names>D</given-names></name><name><surname>Duportail</surname><given-names>M</given-names></name><name><surname>D&#x02019;hooghe</surname><given-names>M</given-names></name><name><surname>Nagels</surname><given-names>G</given-names></name><name><surname>Kerckhofs</surname><given-names>E</given-names></name></person-group><article-title>Multidisciplinary fatigue management programme in multiple sclerosis: a randomized clinical trial</article-title><source>Mult Scler</source><year>2007</year><volume>13</volume><issue>8</issue><fpage>996</fpage><lpage>1003</lpage><pub-id pub-id-type="doi">10.1177/1352458507078392</pub-id><?supplied-pmid 17623738?><pub-id pub-id-type="pmid">17623738</pub-id></element-citation></ref><ref id="CR190"><label>190.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hugos</surname><given-names>C</given-names></name><name><surname>Copperman</surname><given-names>L</given-names></name><name><surname>Fuller</surname><given-names>B</given-names></name><name><surname>Yadav</surname><given-names>V</given-names></name><name><surname>Lovera</surname><given-names>J</given-names></name><name><surname>Bourdette</surname><given-names>D</given-names></name></person-group><article-title>Clinical trial of a formal group fatigue program in multiple sclerosis</article-title><source>Mult Scler</source><year>2010</year><volume>16</volume><issue>6</issue><fpage>724</fpage><lpage>732</lpage><pub-id pub-id-type="doi">10.1177/1352458510364536</pub-id><?supplied-pmid 20375125?><pub-id pub-id-type="pmid">20375125</pub-id></element-citation></ref><ref id="CR191"><label>191.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finlayson</surname><given-names>M</given-names></name><name><surname>Preissner</surname><given-names>K</given-names></name><name><surname>Cho</surname><given-names>C</given-names></name><name><surname>Plow</surname><given-names>M</given-names></name><etal/></person-group><article-title>Randomized trial of a teleconference-delivered fatigue management program for people with multiple sclerosis</article-title><source>Mult Scler</source><year>2011</year><volume>17</volume><issue>9</issue><fpage>1130</fpage><lpage>1140</lpage><pub-id pub-id-type="doi">10.1177/1352458511404272</pub-id><?supplied-pmid 21561960?><pub-id pub-id-type="pmid">21561960</pub-id></element-citation></ref></ref-list></back></article>